Balchem (BCPC) 10-Q 4 Nov 22 2022 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Sep. 30, 2022	Oct. 27, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	1-13648
Entity Registrant Name	Balchem Corporation
Entity Incorporation, State or Country Code	MD
Entity Tax Identification Number	13-2578432
Entity Address, Address Line One	5 Paragon Drive
Entity Address, City or Town	Montvale
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07645
City Area Code	845
Local Phone Number	326-5600
Title of 12(b) Security	Common Stock, par value $.06-2/3 per share
Trading Symbol	BCPC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		32,135,122
Entity Central Index Key	0000009326
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 56,489	$ 103,239
Accounts receivable, net of allowance for doubtful accounts of $1,186 and $928 at September 30, 2022 and December 31, 2021 respectively	140,812	117,408
Inventories	139,464	91,058
Prepaid expenses	6,944	6,116
Prepaid income taxes	3,954	0
Derivative assets	14,540	0
Other current assets	5,908	4,411
Total current assets	368,111	322,232
Property, plant and equipment, net	260,008	237,517
Goodwill	749,035	523,949
Intangible assets with finite lives, net	227,323	94,665
Right of use assets - operating leases	11,617	6,929
Right of use assets - finance lease	2,202	2,359
Other assets	14,712	11,674
Total assets	1,633,008	1,199,325
Current liabilities:
Trade accounts payable	73,121	56,243
Accrued expenses	49,980	43,411
Accrued compensation and other benefits	14,959	19,567
Dividends payable	125	20,886
Income taxes payable	0	1,334
Operating lease liabilities - current	3,727	2,194
Finance lease liabilities - current	173	167
Total current liabilities	142,085	143,802
Revolving loan	462,569	108,569
Deferred income taxes	76,771	46,455
Operating lease liabilities - non-current	8,069	4,811
Finance lease liabilities - non-current	2,172	2,303
Derivative liabilities	0	2,658
Contingent consideration liabilities	30,547	0
Other long-term obligations	14,873	13,712
Total liabilities	737,086	322,310
Commitments and contingencies (Note 16)
Stockholders' equity:
Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding	0	0
Common stock, $0.0667 par value. Authorized 120,000,000 shares; 32,134,902 and 32,287,150 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	2,144	2,154
Additional paid-in capital	124,558	147,716
Retained earnings	816,089	732,138
Accumulated other comprehensive loss	(46,869)	(4,993)
Total stockholders' equity	895,922	877,015
Total liabilities and stockholders' equity	$ 1,633,008	$ 1,199,325

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Allowance for doubtful accounts	$ 1,186	$ 928
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 25	$ 25
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0667	$ 0.0667
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	32,134,902	32,287,150
Common stock, shares outstanding (in shares)	32,134,902	32,287,150

Condensed Consolidated Statemen

Condensed Consolidated Statements of Earnings - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Income Statement [Abstract]
Net sales	$ 244,267	$ 197,869	$ 709,827	$ 585,890
Cost of sales	175,837	136,935	498,015	406,782
Gross margin	68,430	60,934	211,812	179,108
Operating expenses:
Selling expenses	16,590	15,478	49,566	45,248
Research and development expenses	2,996	3,156	9,149	8,804
General and administrative expenses	15,219	9,787	41,216	31,375
Total operating expenses	34,805	28,421	99,931	85,427
Earnings from operations	33,625	32,513	111,881	93,681
Other expenses, net:
Interest expense, net	3,642	556	5,147	1,889
Other income, net	(1,102)	(128)	(1,239)	(295)
Total other expenses (income)	2,540	428	3,908	1,594
Earnings before income tax expense	31,085	32,085	107,973	92,087
Income tax expense	5,836	7,072	24,012	20,932
Net earnings	$ 25,249	$ 25,013	$ 83,961	$ 71,155
Net earnings per common share - basic (in dollars per share)	$ 0.79	$ 0.78	$ 2.62	$ 2.21
Net earnings per common share - diluted (in dollars per share)	$ 0.78	$ 0.77	$ 2.59	$ 2.18

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 25,249	$ 25,013	$ 83,961	$ 71,155
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	(34,874)	(3,362)	(44,667)	(7,981)
Unrealized gain on cash flow hedge	427	341	2,850	1,204
Change in postretirement benefit plans	2	11	(59)	26
Other comprehensive income (loss)	(34,445)	(3,010)	(41,876)	(6,751)
Comprehensive (loss) income	$ (9,196)	$ 22,003	$ 42,085	$ 64,404

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Common Stock	Additional Paid-in Capital
Beginning balance at Dec. 31, 2020	$ 828,233	$ 656,740	$ 4,173	$ 2,160	$ 165,160
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,372,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	23,411	23,411
Other comprehensive income (loss)	(5,624)		(5,624)
Repurchases of common stock	(1,596)			$ (1)	(1,595)
Repurchases of common stock (in shares)				(13,475)
Shares and options (cancelled) issued under stock plans (in shares)				92,784
Shares and options issued under stock plans	5,068			$ 6	5,062
Ending balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	168,627
Ending balance, common stock (in shares) at Mar. 31, 2021				32,451,930
Beginning balance at Dec. 31, 2020	828,233	656,740	4,173	$ 2,160	165,160
Beginning balance, common stock (in shares) at Dec. 31, 2020				32,372,621
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	71,155
Other comprehensive income (loss)	(6,751)
Ending balance at Sep. 30, 2021	889,078	727,895	(2,578)	$ 2,161	161,600
Ending balance, common stock (in shares) at Sep. 30, 2021				32,382,637
Beginning balance at Mar. 31, 2021	849,492	680,151	(1,451)	$ 2,165	168,627
Beginning balance, common stock (in shares) at Mar. 31, 2021				32,451,930
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	22,731	22,731
Other comprehensive income (loss)	1,883		1,883
Repurchases of common stock	(9,240)			$ (5)	(9,235)
Repurchases of common stock (in shares)				(72,649)
Shares and options (cancelled) issued under stock plans (in shares)				25,493
Shares and options issued under stock plans	4,776			$ 2	4,774
Ending balance at Jun. 30, 2021	869,642	702,882	432	$ 2,162	164,166
Ending balance, common stock (in shares) at Jun. 30, 2021				32,404,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	25,013	25,013
Other comprehensive income (loss)	(3,010)		(3,010)
Repurchases of common stock	(7,926)			$ (4)	(7,922)
Repurchases of common stock (in shares)				(61,075)
Shares and options (cancelled) issued under stock plans (in shares)				38,938
Shares and options issued under stock plans	5,359			$ 3	5,356
Ending balance at Sep. 30, 2021	889,078	727,895	(2,578)	$ 2,161	161,600
Ending balance, common stock (in shares) at Sep. 30, 2021				32,382,637
Beginning balance at Dec. 31, 2021	877,015	732,138	(4,993)	$ 2,154	147,716
Beginning balance, common stock (in shares) at Dec. 31, 2021				32,287,150
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	28,930	28,930
Other comprehensive income (loss)	(1,296)		(1,296)
Repurchases of common stock	(34,599)			$ (16)	(34,583)
Repurchases of common stock (in shares)				(245,685)
Dividends	(10)	(10)
Shares and options (cancelled) issued under stock plans (in shares)				74,604
Shares and options issued under stock plans	3,642			$ 4	3,638
Ending balance at Mar. 31, 2022	873,682	761,058	(6,289)	$ 2,142	116,771
Ending balance, common stock (in shares) at Mar. 31, 2022				32,116,069
Beginning balance at Dec. 31, 2021	877,015	732,138	(4,993)	$ 2,154	147,716
Beginning balance, common stock (in shares) at Dec. 31, 2021				32,287,150
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	83,961
Other comprehensive income (loss)	(41,876)
Ending balance at Sep. 30, 2022	895,922	816,089	(46,869)	$ 2,144	124,558
Ending balance, common stock (in shares) at Sep. 30, 2022				32,134,902
Beginning balance at Mar. 31, 2022	873,682	761,058	(6,289)	$ 2,142	116,771
Beginning balance, common stock (in shares) at Mar. 31, 2022				32,116,069
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	29,782	29,782
Other comprehensive income (loss)	(6,135)		(6,135)
Repurchases of common stock	(600)				(600)
Repurchases of common stock (in shares)				(4,976)
Shares and options (cancelled) issued under stock plans (in shares)				9,500
Shares and options issued under stock plans	4,641			$ 1	4,640
Ending balance at Jun. 30, 2022	901,370	790,840	(12,424)	$ 2,143	120,811
Ending balance, common stock (in shares) at Jun. 30, 2022				32,120,593
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net earnings	25,249	25,249
Other comprehensive income (loss)	(34,445)		(34,445)
Repurchases of common stock	(46)				(46)
Repurchases of common stock (in shares)				(361)
Shares and options (cancelled) issued under stock plans (in shares)				14,670
Shares and options issued under stock plans	3,794			$ 1	3,793
Ending balance at Sep. 30, 2022	$ 895,922	$ 816,089	$ (46,869)	$ 2,144	$ 124,558
Ending balance, common stock (in shares) at Sep. 30, 2022				32,134,902

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net earnings	$ 83,961	$ 71,155
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation and amortization	37,958	36,622
Stock compensation expense	9,838	8,809
Deferred income taxes	1,513	(806)
Provision for doubtful accounts	379	105
Unrealized gain on foreign currency transaction and deferred compensation	(1,262)	(534)
Asset impairment charge	23	0
Loss/(gain) on disposal of assets	259	(996)
Changes in assets and liabilities
Accounts receivable	(14,678)	(14,088)
Inventories	(30,370)	(11,736)
Prepaid expenses and other current assets	(690)	(3,793)
Accounts payable and accrued expenses	14,358	30,467
Income taxes	(5,732)	(681)
Other	1,324	1,499
Net cash provided by operating activities	96,881	116,023
Cash flows from investing activities:
Cash paid for acquisitions, net of cash acquired	(365,780)	0
Capital expenditures and intangible assets acquired	(35,793)	(22,391)
Proceeds from insurance and sale of assets	198	1,272
Investment in affiliates	(150)	0
Net cash used in investing activities	(401,525)	(21,119)
Cash flows from financing activities:
Proceeds from revolving loan	435,000	5,000
Principal payments on revolving loan	(81,000)	(60,000)
Principal payments on acquired debt	(30,782)	0
Cash paid for financing costs	(1,232)	0
Principal payments on finance lease	(125)	(118)
Proceeds from stock options exercised	2,172	6,351
Dividends paid	(20,708)	(18,704)
Purchase of common stock	(35,245)	(18,762)
Net cash provided by (used in) financing activities	268,080	(86,233)
Effect of exchange rate changes on cash	(10,186)	(3,229)
(Decrease) increase in cash and cash equivalents	(46,750)	5,442
Cash and cash equivalents beginning of period	103,239	84,571
Cash and cash equivalents end of period	$ 56,489	$ 90,013

CONDENSED CONSOLIDATED FINANCIA

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The condensed consolidated financial statements presented herein have been prepared in accordance with the accounting policies described in the December 31, 2021 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2021. The condensed consolidated financial statements reflect the operations of Balchem Corporation and its subsidiaries (the "Company" or "Balchem"). All intercompany balances and transactions have been eliminated in consolidation. In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal, recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 (the "Exchange Act") and therefore do not include some information and notes necessary to conform to annual reporting requirements. The results of operations for the three and nine months ended September 30, 2022 are not necessarily indicative of the operating results expected for the full year or any interim period. Certain reclassifications have been made to prior period amounts to conform with the current period's presentation. Recent Accounting Pronouncements Recently Adopted Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted the Standard Update in 2021. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its existing interest rate swap and replaced LIBOR with 1-month CME Term SOFR (see Note 20, "Derivative Instruments and Hedging Activities "). The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on the Company's consolidated financial statements and disclosures.

SIGNIFICANT ACQUISITIONS

SIGNIFICANT ACQUISITIONS	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
SIGNIFICANT ACQUISITIONS	SIGNIFICANT ACQUISITIONS Cardinal Associates Inc. ("Bergstrom") On August 30, 2022, the Company's wholly-owned subsidiary Albion Laboratories, Inc. ("Albion") entered into a Stock Purchase Agreement, and closed on such transaction with Cardinal Associates Inc. ("Cardinal"), a corporation organized under the laws of the State of Washington, pursuant to which Albion acquired Cardinal and its Bergstrom Nutrition business (collectively, "Bergstrom"). Bergstrom Nutrition is a leading science-based manufacturer of methylsulfonylmethane (MSM), based in Vancouver, Washington. MSM is a widely used nutritional ingredient with strong scientific evidence supporting its benefits for joint health, sports nutrition, skin and beauty, healthy aging, and pet health. Bergstrom Nutrition's MSM brand "OptiMSM ® " delivers the highest quality and purity MSM on the market and is the only brand of MSM with a U.S. GRAS "generally regarded as safe" designation. The addition of OptiMSM ® to the Company's portfolio within Human Nutrition & Health and Animal Nutrition & Health segments provides a synergistic scientific advantage in Balchem's key strategic therapeutic focus areas such as longevity and performance and is a strong fit with Balchem's specialty, science-backed mineral products. The Company made payments of $70,892 for the acquisition, amounting to $69,740 to the former shareholders and $1,152 to pay off Bergstrom's bank debt and certain other obligations. Net of cash acquired of $773, total payments made to the former shareholders of Bergstrom on the acquisition date were $68,967. The acquisition was primarily financed through the 2022 Credit Agreement (see Note 8, "Revolving Loan"). In connection with this transaction, the former shareholders of Bergstrom have an opportunity to receive an additional payment if certain financial performance targets and other metrics are met, and therefore we recorded a contingent consideration liability of $7,835 as of September 30, 2022. The goodwill of $34,060 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to both the Human Nutrition & Health and Animal Nutrition & Health business segments. For tax purposes, a joint election under 338(h)(10) was made to treat the stock acquisition as a deemed asset acquisition, therefore generating tax amortizable goodwill. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed: Cash and cash equivalents $ 773 Accounts receivable 4,699 Inventories 3,922 Property, plant and equipment 2,700 Right of use assets 866 Customer relationships 26,500 Developed technology 4,700 Trademarks 2,300 Other assets 197 Accounts payable (685) Bank debt (206) Lease liabilities (871) Other liabilities (1,380) Goodwill 34,060 Total consideration on acquisition date 77,575 Contingent consideration liability (7,835) Amount paid to shareholders 69,740 To pay off bank debt and certain other obligations 1,152 Total amount paid $ 70,892 The estimated fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions, which are subject to change. In preparing our preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. The purchase price and related allocation of assets acquired and liabilities assumed is preliminary pending management's final review of fair value calculations. Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined. Transaction and integration costs related to the Bergstrom acquisition are included in general and administrative expenses and were $593 and $668 for the three and nine months ended September 30, 2022, respectively. Kechu BidCo AS and Its Subsidiary Companies ("Kappa") On June 21, 2022, Balchem Corporation and its wholly-owned subsidiary, Balchem B.V., completed the acquisition of Kechu BidCo AS and its subsidiary companies, including Kappa Bioscience AS, a leading science-based manufacturer of specialty vitamin K2 for the human nutrition industry, headquartered in Oslo, Norway (all acquired companies collectively referred to as “Kappa”). The Company made payments of approximately kr3,301,341 ("kr" indicates the Norwegian krone) on the acquisition date, amounting to approximately kr2,997,669 to the former shareholder and approximately kr303,672 to Kappa's lenders to pay off all Kappa bank debt. Net of cash acquired of kr63,064, total payments on the acquisition date were kr3,238,277. Considering net cash acquired of $6,365, these payments translated to approximately $326,820 paid on the acquisition date, amounting to $302,537 paid to the former shareholder and approximately $30,648 to Kappa's lenders. The acquisition was primarily financed through the 2018 Credit Agreement (see Note 8, "Revolving Loan"). In connection with this transaction, the seller has an opportunity to receive an additional payment in 2024 if certain financial performance targets and other metrics are met, and therefore we recorded contingent consideration of kr245,000 in the second quarter of 2022 (translated to $22,712 as of September 30, 2022). Kappa manufactures specialty vitamin K2, a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance. Primarily, vitamin K2 supports the transport and distribution of calcium in the body. Vitamin K2 is important at all life stages, from pregnancy and early life to healthy aging. Kappa's K2VITAL® branded vitamin K2 is the leading synthetic vitamin K2 and is backed by strong intellectual property and a deep clinical research portfolio. The acquisition strengthens the Company's scientific and technical expertise, geographic reach, and marketplace leadership, which should ultimately lead to accelerated growth for the Company's portfolios within the Human Nutrition & Health segment. The goodwill of $217,570 that arose on the acquisition date consists largely of expected synergies, including the combined entities' experience and technical problem-solving capabilities, and acquired workforce. The goodwill is assigned to the Human Nutrition & Health business segment and is not deductible for income tax purposes. The following table summarizes the estimated fair values of the assets acquired and liabilities assumed. The transactions were completed in Norwegian kroner ("NOK") and the amounts were translated to U.S. dollars ("USD") using the foreign currency exchange rate as of June 21, 2022. Cash and cash equivalents $ 6,365 Accounts receivable 8,036 Inventories 17,701 Property, plant and equipment 9,854 Right of use assets 3,349 Customer relationships 110,012 Developed technology 17,662 Trademarks 6,055 Other assets 2,399 Accounts payable (3,301) Bank debt (30,648) Lease liabilities (3,349) Other liabilities (4,373) Deferred income taxes, net (30,069) Goodwill 217,570 Total consideration on acquisition date 327,263 Contingent consideration liability (24,726) Net gain on foreign currency exchange forward contracts (512) Amount paid to shareholders 302,025 Kappa bank debt paid on acquisition date 30,648 Total amount paid on acquisition date $ 332,673 The estimated fair value of tangible and intangible assets acquired and liabilities assumed is based on management’s estimates and assumptions, which are subject to change. In preparing our preliminary fair value estimates of the intangible assets and certain tangible assets acquired, management, among other things, consulted an independent advisor. Valuation methods utilized include net realizable value for inventory, multi-period excess earnings method for customer relationships, the relief from royalty method for other intangible assets, and a scenario-based approach for the contingent consideration. The purchase price and related allocation of assets acquired and liabilities assumed is preliminary pending management's final review of fair value calculations and deferred tax liabilities related to certain non-deductible assets. Customer relationships are amortized over a 15-year period utilizing a percentage of excess earnings over economic life method. The corporate trademark and product trademarks are amortized over 2 years and 10 years, respectively, and developed technology is amortized over 12 years, utilizing the straight-line method as the consumption pattern of the related economic benefits cannot be reliably determined. Transaction and integration costs related to the Kappa acquisition are included in general and administrative expenses and were $989 and $1,440 for both the three and nine months ended September 30, 2022. There were no such amounts related to this acquisition for the three and nine months ended September 30, 2021.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY STOCK-BASED COMPENSATION The Company’s results for the three and nine months ended September 30, 2022 and 2021 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Increase/(Decrease) for the Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Cost of sales $ 386 $ 444 $ 1,062 $ 1,188 Operating expenses 2,563 2,451 8,776 7,621 Net earnings (2,251) (2,232) (7,563) (6,801) As allowed by ASC 718, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest. The Company’s stock incentive plans allow for the granting of stock awards and options to purchase common stock. Both incentive stock options and nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of September 30, 2022, the plans had 407,630 shares available for future awards. Compensation expense for stock options and stock awards is recognized on a straight-line basis over the vesting period, generally three Option activity for the nine months ended September 30, 2022 and 2021 is summarized below: For the nine months ended September 30, 2022 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2021 867 $ 88.19 $ 69,711 Granted 239 139.04 Exercised (31) 70.06 Forfeited (12) 125.05 Canceled — — Outstanding as of September 30, 2022 1,063 $ 99.74 $ 27,308 6.6 Exercisable as of September 30, 2022 656 $ 81.45 $ 26,312 5.2 For the nine months ended September 30, 2021 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.12 Exercised (100) 63.49 Forfeited (10) 106.93 Canceled (1) 74.57 Outstanding as of September 30, 2021 876 $ 87.91 $ 50,090 6.6 Exercisable as of September 30, 2021 540 $ 74.81 $ 37,961 5.5 ASC 718 requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award. The weighted average fair values of the stock options granted under the Plans were calculated using either the Black-Scholes model or the Binomial model, whichever was deemed to be most appropriate. For the nine months ended September 30, 2022, the fair value of each option grant was estimated on the date of the grant using the following weighted average assumptions: dividend yields of 0.5%; expected volatilities of 30%; risk-free interest rates of 2.8%; and expected lives of 7.3 years. For nine months ended September 30, 2021, the fair value of each option grant was estimated on the date of the grant using the following weighted average assumptions: dividend yields of 0.5%; expected volatilities of 33%; risk-free interest rates of 0.5%; and expected lives of 4.9 years. The Company used a projected expected life for each award granted based on historical experience of employees’ exercise behavior. Expected volatility is based on the Company’s historical volatility levels. Dividend yields are based on the Company’s historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury Zero coupon issues with a remaining term equal to the expected life. Other information pertaining to option activity during the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Weighted-average fair value of options granted $ 48.55 $ — $ 44.77 $ 33.11 Total intrinsic value of stock options exercised ($000s) $ 815 $ 3,196 $ 1,964 $ 6,927 Non-vested restricted stock activity for the nine months ended September 30, 2022 and 2021 is summarized below: Nine Months Ended September 30, 2022 2021 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 166 $ 99.70 159 $ 90.71 Granted 40 137.03 38 119.59 Vested (78) 81.11 (16) 86.79 Forfeited (7) 116.72 (5) 95.71 Non-vested balance as of September 30 121 $ 122.96 176 $ 97.17 Non-vested performance share activity for the nine months ended September 30, 2022 and 2021 is summarized below: Nine Months Ended September 30, 2022 2021 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 69 $ 110.72 71 $ 91.99 Granted 39 114.22 36 108.74 Vested (35) 53.17 (24) 70.64 Forfeited (3) 84.09 (11) 74.57 Non-vested balance as of September 30 70 $ 127.69 72 $ 110.22 The performance share (“PS”) awards provide the recipients the right to receive a certain number of shares of the Company’s common stock in the future, subject to an EBITDA performance hurdle, where vesting is dependent upon the Company achieving a certain EBITDA percentage growth over the performance period, and relative total shareholder return (TSR) where vesting is dependent upon the Company’s TSR performance over the performance period relative to a comparator group consisting of the Russell 2000 index constituents. Expense is measured based on the fair value at the date of grant utilizing a Black-Scholes methodology to produce a Monte-Carlo simulation model which allows for the incorporation of the performance hurdles that must be met before the PS vests. The assumptions used in the fair value determination were risk free interest rates of 1.8% and 0.2%; dividend yields of 0.5% and 0.6%; volatilities of 32% and 33%; and initial TSR’s of -15.7% and 11.7%, in each case for the nine months ended September 30, 2022 and 2021, respectively. Expense is estimated based on the number of shares expected to vest, assuming the requisite service period is rendered and the probable outcome of the performance condition is achieved. The estimate is revised if subsequent information indicates that the actual number of shares likely to vest differs from previous estimates. Expense is ultimately adjusted based on the actual achievement of service and performance targets. The PS will cliff vest 100% at the end of the third year following the grant in accordance with the performance metrics set forth. As of September 30, 2022 and 2021, there were $23,665 and $16,498, respectively, of total unrecognized compensation costs related to non-vested share-based compensation arrangements granted under the plans. As of September 30, 2022, the unrecognized compensation cost is expected to be recognized over a weighted-average period of approximately 2.1 years. The Company estimates that share-based compensation expense for the year ended December 31, 2022 will be approximately $13,500. REPURCHASE OF COMMON STOCK The Company's Board of Directors has approved a stock repurchase program. The total authorization under this program is 3,763,038 shares. Since the inception of the program in June 1999, a total of 3,069,266 shares have been purchased. The Company’s prior presentation of reflecting treasury stock separately within stockholders’ equity has been adjusted to conform to the presentation prescribed by the State of Maryland, where the Company is incorporated. In connection therewith, adjustments to balances previously reflected as treasury stock of $11,080, $8,472, $2,210, and $7,873 as of September 30, 2021, June 30, 2021, March 31, 2021, and December 31, 2020, respectively, were made to the condensed consolidated statements of changes in stockholders’ equity and prior references to “Treasury shares purchased” were updated to “Repurchases of common stock”, accordingly. There was no impact to total stockholders’ equity in any of the years presented as a result of these updates. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it is advisable to do so based on its assessment of corporate cash flow, market conditions and other factors. The Company also repurchases shares from employees in connection with settlement of transactions under the Company's equity incentive plans. During the nine months ended September 30, 2022 and 2021, the Company purchased 251,022 and 147,199 shares, respectively, from open market purchases and from employees on a net-settlement basis to provide cash to employees to cover the associated employee payroll taxes. These shares were purchased at an average cost of $140.41 and $127.46, respectively.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories at September 30, 2022 and December 31, 2021 consisted of the following: September 30, 2022 December 31, 2021 Raw materials $ 41,371 $ 28,639 Work in progress 11,879 10,563 Finished goods 86,214 51,856 Total inventories $ 139,464 $ 91,058

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
PROPERTY, PLANT AND EQUIPMENT	PROPERTY, PLANT AND EQUIPMENT Property, plant and equipment at September 30, 2022 and December 31, 2021 are summarized as follows: September 30, 2022 December 31, 2021 Land $ 10,993 $ 11,692 Building 90,239 89,602 Equipment 267,611 253,995 Construction in progress 73,163 52,930 442,006 408,219 Less: accumulated depreciation 181,998 170,702 Property, plant and equipment, net $ 260,008 $ 237,517

INTANGIBLE ASSETS

INTANGIBLE ASSETS	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS The Company had goodwill in the amount of $749,035 and $523,949 as of September 30, 2022 and December 31, 2021, respectively, subject to the provisions of ASC 350, “Intangibles-Goodwill and Other.” The increase in goodwill is the result of the acquisitions of Kappa and Bergstrom, partially offset by the change due to foreign exchange translation adjustments. Refer to Note 2, "Significant Acquisitions", for more information. Identifiable intangible assets with finite lives at September 30, 2022 and December 31, 2021 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at 9/30/2022 Gross Carrying Amount at 12/31/2021 Accumulated Amortization at 12/31/2021 Customer relationships & lists 10-20 $ 361,747 $ 185,381 $ 240,059 $ 173,489 Trademarks & trade names 2-17 50,487 32,285 43,116 28,985 Developed technology 5-12 40,816 15,524 20,234 14,607 Other 2-18 24,600 17,137 23,921 15,584 $ 477,650 $ 250,327 $ 327,330 $ 232,665 Amortization of identifiable intangible assets was approximately $7,922 and $19,683 for the three and nine months ended September 30, 2022, respectively, and $6,155 and $18,868 for the three and nine months ended September 30, 2021, respectively. Assuming no change in the gross carrying value of identifiable intangible assets, estimated amortization expense is $5,300 for the remainder of 2022, $30,188 for 2023, $21,740 for 2024, $17,906 for 2025, $17,362 for 2026 and $16,553 for 2027. At September 30, 2022 and December 31, 2021, there were no identifiable intangible assets with indefinite useful lives as defined by ASC 350. Identifiable intangible assets are reflected in “Intangible assets with finite lives, net” in the Company’s condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the nine months ended September 30, 2022 and 2021.

EQUITY-METHOD INVESTMENT

EQUITY-METHOD INVESTMENT	9 Months Ended
	Sep. 30, 2022
Equity Method Investments and Joint Ventures [Abstract]
EQUITY-METHOD INVESTMENT	EQUITY-METHOD INVESTMENT In 2013, the Company and Eastman Chemical Company (formerly Taminco Corporation) formed a joint venture (66.66% / 33.34% ownership), St. Gabriel CC Company, LLC, to design, develop, and construct an expansion of the Company’s St. Gabriel aqueous choline chloride plant. The Company contributed the St. Gabriel plant, at cost, and all continued expansion and improvements are funded by the owners. The joint venture became operational as of July 1, 2016. St. Gabriel CC Company, LLC is a Variable Interest Entity (VIE) because the total equity at risk is not sufficient to permit the joint venture to finance its own activities without additional subordinated financial support. Additionally, voting rights (2 votes each) are not proportionate to the owners’ obligation to absorb expected losses or receive the expected residual returns of the joint venture. The Company receives up to 2/3 of the production offtake capacity and absorbs operating expenses approximately proportional to the actual percentage of offtake. The joint venture is accounted for under the equity method of accounting since the Company is not the primary beneficiary as the Company does not have the power to direct the activities of the joint venture that most significantly impact its economic performance. The Company recognized a loss of $140 and $420 for the three and nine months ended September 30, 2022, respectively, and $142 and $416 for the three and nine months ended September 30, 2021, respectively, relating to its portion of the joint venture's expenses in other expense. The Company made capital contributions to the investment totaling $89 and $222 for the three and nine months ended September 30, 2022, respectively, and $46 and $31 for the three and nine months ended September 30, 2021, respectively. The carrying value of the joint venture at September 30, 2022 and December 31, 2021 was $4,301 and $4,499, respectively, and is recorded in "Other assets."

REVOLVING LOAN

REVOLVING LOAN	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
REVOLVING LOAN	REVOLVING LOANOn June 27, 2018, the Company and a bank syndicate entered into a credit agreement (the "2018 Credit Agreement"), which provided for revolving loans up to $500,000, due on June 27, 2023. During the second quarter of 2022, the Company borrowed $345,000 under the 2018 Credit Agreement to fund the Kappa acquisition (see Note 2, "Significant Acquisitions"). On July 27, 2022, the Company entered into an Amended and Restated Credit Agreement (the "2022 Credit Agreement") with certain lenders in the form of a senior secured revolving credit facility, due on July 27, 2027. The 2022 Credit Agreement allows for up to $550,000 of borrowing. The loans may be used for working capital, letters of credit, and other corporate purposes and may be drawn upon at the Company’s discretion. The Company used initial proceeds from the 2022 Credit Agreement to repay the outstanding balance of $433,569 due in June 2023 under the 2018 Credit Agreement. During the third quarter of 2022, the Company borrowed another $70,000 to fund the Bergstrom acquisition (see Note 2, "Significant Acquisitions"). As of September 30, 2022, the total balance outstanding on the 2022 Credit Agreement amounted to $462,569. As of December 31, 2021, the total balance outstanding on the 2018 Credit Agreement amounted to $108,569. There are no installment payments required on the revolving loans; they may be voluntarily prepaid in whole or in part without premium or penalty, and all outstanding amounts are due on the maturity date. In connection with the entering into the Amended and Restated Credit Agreement, the Company also modified its existing interest rate swap under the relief provided for in ASC 848, "Reference Rate Reform" (see Note 20 "Derivative Instruments and Hedging Activities"). Amounts outstanding under the 2022 Credit Agreement are subject to an interest rate equal to a fluctuating rate as defined by the 2022 Credit Agreement plus an applicable rate. The applicable rate is based upon the Company’s consolidated net leverage ratio, as defined in the 2022 Credit Agreement, and the interest rate was 4.214% at September 30, 2022. The Company is also required to pay a commitment fee on the unused portion of the revolving loan, which is based on the Company’s consolidated net leverage ratio as defined in the 2022 Credit Agreement and ranges from 0.15% to 0.225% (0.175% at September 30, 2022). The unused portion of the revolving loan amounted to $87,431 at September 30, 2022. The Company is also required to pay, as applicable, letter of credit fees, administrative agent fees, and other fees to the arrangers and lenders. Costs associated with the issuance of the revolving loans and certain costs associated with the issuance of the extinguished debt instrument are capitalized and amortized on a straight-line basis over the term of the 2022 Credit Agreement, which is not materially different than the effective interest method. Capitalized costs net of accumulated amortization totaled $1,389 and $421 at September 30, 2022 and December 31, 2021, respectively, and are included in other assets on the condensed consolidated balance sheets. Amortization expense pertaining to these costs totaled $121 and $262 for the three and nine months ended September 30, 2022 and $71 and $212 for the three and nine months ended September 30, 2021, respectively, and are included in "Interest expense" in the accompanying condensed consolidated statements of earnings. The 2022 Credit Agreement contains quarterly covenants requiring the consolidated leverage ratio to be less than a certain maximum ratio and the consolidated interest coverage ratio to exceed a certain minimum ratio. At September 30, 2022, the Company was in compliance with these covenants. Indebtedness under the Company’s loan agreements is secured by assets of the Company.

NET EARNINGS PER SHARE

NET EARNINGS PER SHARE	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
NET EARNINGS PER SHARE	NET EARNINGS PER SHARE The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net Earnings - Basic and Diluted $ 25,249 $ 25,013 $ 83,961 $ 71,155 Shares (000s) Weighted Average Common Shares - Basic 32,010 32,194 32,017 32,227 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 357 450 375 424 Weighted Average Common Shares - Diluted 32,367 32,644 32,392 32,651 Net Earnings Per Share - Basic $ 0.79 $ 0.78 $ 2.62 $ 2.21 Net Earnings Per Share - Diluted $ 0.78 $ 0.77 $ 2.59 $ 2.18 The number of anti-dilutive shares were 362,203 and 369,183 for the three and nine months ended September 30, 2022, respectively, and 151,924 and 156,238 for the three and nine months ended September 30, 2021 , respectively. Anti-dilutive shares could potentially dilute basic earnings per share in future periods and therefore, were not included in diluted earnings per share.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three months ended September 30, 2022 and 2021, was 18.8% and 22.0%, respectively, and 22.2% and 22.7% for the nine months ended September 30, 2022 and 2021. The decrease in the effective tax rate for the three months ended September 30, 2022 compared to the three months ended September 30, 2021 was primarily due to a favorable provision to return adjustment related to an increase in certain tax credits and deductions. The decrease in the effective tax rate for the nine months ended September 30, 2022 compared to the nine months ended September 30, 2021 was primarily due to a favorable provision to return adjustment related to an increase in certain tax credits and deductions, which was offset by a change in mix of earnings in higher taxing jurisdictions. Balchem will continue to evaluate and analyze the impact of the U.S. Tax Cuts and Jobs Act that was enacted on December 22, 2017 and the additional guidance that has been issued, and may be issued, by the U.S. Department of Treasury, the Securities and Exchange Commission ("SEC"), and/or the Financial Accounting Standards Board ("FASB") regarding this act. Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and would establish a valuation allowance if it believed that such assets may not be recovered, taking into consideration historical operating results, expectations of future earnings, changes in its operations and the expected timing of the reversals of existing temporary differences. The Company accounts for uncertainty in income taxes utilizing ASC 740-10, "Income Taxes". ASC 740-10 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. It prescribes a recognition threshold and measurement attribute for financial statement disclosure of tax positions taken or expected to be taken. This interpretation also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, and disclosures. The application of ASC 740-10 requires judgment related to the uncertainty in income taxes and could impact our effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of September 30, 2022, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2017. As of September 30, 2022 and December 31, 2021, the Company had approximately $5,690 and $5,881, respectively, of unrecognized tax benefits, which are included in "Other long-term obligations" on the Company’s condensed consolidated balance sheets. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of "Income tax expense" in the condensed consolidated statements of earnings. The total amounts of accrued interest and penalties related to uncertain tax positions at September 30, 2022 and December 31, 2021 were approximately $2,167 and $2,106, respectively, and are included in "Other long-term obligations."

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Balchem Corporation reports three business segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated." Human Nutrition & Health The Human Nutrition & Health ("HNH") segment provides human grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The Company's mineral amino acid chelates, specialized mineral salts, and mineral complexes are used as raw materials for inclusion in premier human nutrition products. Proprietary technologies have been combined to create an organic molecule in a form the body can readily assimilate. Sales growth for human nutrition applications is reliant on differentiation from lower-cost competitive products through scientific data, intellectual property and customers' appreciation of brand value. Consequently, the Company makes investments in such activities for long-term value differentiation. This segment also serves the food and beverage industry for beverage, bakery, dairy, confectionary, and savory manufacturers. The Company partners with its customers from ideation through commercialization to bring on-trend beverages, baked goods, confections, dairy and meat products to market. The Company has expertise in trends analysis and product development. With its strong manufacturing capabilities in customized spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, ice cream bases and variegates, the Company is a one-stop solutions provider for beverage and dairy product development needs. Additionally, this segment provides microencapsulation solutions to a variety of applications in food, pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, sports and protein bars, dietary plans, and nutritional supplements. The Company also creates cereal systems for ready-to-eat cereals, grain-based snacks, and cereal based ingredients. Through the Kappa and Bergstrom acquisitions, respectively, this segment recently began manufacturing specialty vitamin K2, which is a fast-growing specialty vitamin that plays a crucial role in the human body for bone health, heart health, immunity, and athletic performance, and MSM, which is a widely used nutritional ingredient that provides benefits for joint health, sports nutrition, skin and beauty, and healthy aging. Animal Nutrition & Health The Company’s Animal Nutrition & Health ("ANH") segment provides nutritional products derived from its microencapsulation and chelation technologies in addition to basic choline chloride. For ruminant animals, the Company’s microencapsulated products boost health and milk production by delivering nutrient supplements that are biologically available, providing required nutritional levels. The Company’s proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals and is marketed for use in animal feed throughout the world. ANH also manufactures and supplies choline chloride, an essential nutrient for monogastric animal health, predominantly to the poultry, pet and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. In poultry, choline deficiency can result in reduced growth rates and perosis in young birds, while in swine production choline is a necessary and required component of gestating and lactating sow diets for both liver health and prevention of leg deformity. Through the Bergstrom acquisition, this segment recently began manufacturing MSM, which is a widely used nutritional ingredient that provides benefits for pet health. Sales of value-added encapsulated products are highly dependent on overall industry economics as well as the Company's ability to leverage the results of university and field research on the animal health and production benefits of our products. Management believes that success in the commodity-oriented basic choline chloride marketplace is highly dependent on the Company’s ability to maintain its strong reputation for excellent product quality and customer service. The Company continues to drive production efficiencies in order to maintain its competitive-cost position to effectively compete in a competitive global marketplace. Specialty Products The Company re-packages and distributes a number of performance gases and chemicals for various uses by its customers, notably ethylene oxide, propylene oxide, and ammonia. Ethylene oxide is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without negatively impacting the performance of the device being sterilized. Contract sterilizers and medical device manufacturers are principal customers for this product. Propylene oxide is marketed and sold as a fumigant to aid in the control of insects and microbiological spoilage; and to reduce bacterial and mold contamination in certain shelled and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs and prunes, and for various chemical synthesis applications, such as increasing paint durability and manufacturing specialty starches and textile coatings Ammonia is used primarily as a refrigerant, and also for heat treatment of metals and various chemical synthesis applications, and is distributed in reusable and recyclable drum and cylinder packaging approved for use in the countries these products are shipped to. The Company’s performance gases and chemicals are distributed worldwide in specially designed, reusable and recyclable drum and cylinder packaging, to assure compliance with safety, quality and environmental standards as outlined by the applicable regulatory agencies in the countries our products are shipped to. The Company’s inventory of these specially built drums and cylinders, along with its five filling facilities, represents a significant capital investment. The Company also sells single use canisters for use in sterilizing re-usable devices typically processed in autoclave units in hospitals. The Company’s micronutrient agricultural nutrition business sells chelated minerals primarily to producers of high value crops. The Company has a unique and patented two-step approach to solving mineral deficiency in plants to optimize health, yield and shelf-life. First, the Company determines optimal mineral balance for plant health. The Company then has a foliar applied Metalosate ® product range, utilizing patented amino acid chelate technology. Its products quickly and efficiently deliver mineral nutrients. As a result, the farmer/grower gets healthier crops that are more resistant to disease and pests, larger yields and healthier food for the consumer with extended shelf life for produce being shipped long distances. The segment information is summarized as follows: Business Segment Assets September 30, December 31, Human Nutrition & Health $ 1,169,395 $ 727,131 Animal Nutrition & Health 189,652 158,971 Specialty Products 169,817 184,628 Other and Unallocated (1) 104,144 128,595 Total $ 1,633,008 $ 1,199,325 Business Segment Net Sales Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 142,655 $ 111,200 $ 396,728 $ 327,187 Animal Nutrition & Health 65,604 56,192 197,546 161,821 Specialty Products 29,641 27,615 99,622 89,645 Other and Unallocated (2) 6,367 2,862 15,931 7,237 Total $ 244,267 $ 197,869 $ 709,827 $ 585,890 Business Segment Earnings Before Income Taxes Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 20,584 $ 19,801 $ 64,592 $ 58,512 Animal Nutrition & Health 8,036 7,442 26,943 16,059 Specialty Products 7,105 6,455 24,785 23,373 Other and Unallocated (2) (2,100) (1,185) (4,439) (4,263) Interest and other expense (2,540) (428) (3,908) (1,594) Total $ 31,085 $ 32,085 $ 107,973 $ 92,087 Depreciation/Amortization Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 9,569 $ 7,472 $ 24,316 $ 22,486 Animal Nutrition & Health 1,681 1,932 5,010 5,512 Specialty Products 1,839 1,997 5,670 6,351 Other and Unallocated (2) 1,008 758 2,962 2,273 Total $ 14,097 $ 12,159 $ 37,958 $ 36,622 Capital Expenditures Nine Months Ended 2022 2021 Human Nutrition & Health $ 22,513 $ 14,492 Animal Nutrition & Health 8,748 4,557 Specialty Products 3,139 2,281 Other and Unallocated (2) 550 238 Total $ 34,950 $ 21,568 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,640 and $2,816 for the three and nine months ended September 30, 2022, respectively, and $305 and $1,005 for the three and nine months ended September 30, 2021, respectively, and (ii) Unallocated amortization expense of $855 and $2,475 for the three and nine months ended September 30, 2022, respectively, and $675 and $2,024 for the three and nine months ended September 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that were included in interest expense in the Company's condensed consolidated statements of earnings.

REVENUE

REVENUE	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
REVENUE	REVENUE Revenue Recognition Revenues are recognized when control of the promised goods is transferred to customers, in an amount that reflects the consideration the Company expects to realize in exchange for those goods. The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product Sales $ 233,823 $ 188,573 $ 677,136 $ 557,683 Co-manufacturing 8,109 7,473 26,235 21,629 Consignment 1,484 829 4,064 3,260 Product Sales Revenue 243,416 196,875 707,435 582,572 Royalty Revenue 851 994 2,392 3,318 Total Revenue $ 244,267 $ 197,869 $ 709,827 $ 585,890 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 174,564 $ 142,313 $ 518,131 $ 427,352 Foreign Countries 69,703 55,556 191,696 158,538 Total Revenue $ 244,267 $ 197,869 $ 709,827 $ 585,890 Product Sales Revenues The Company’s primary operation is the manufacturing and sale of health and nutrition ingredient products, in which the Company receives an order from a customer and fulfills that order. The Company’s product sales are considered point-in-time revenue and consist of three sub-streams: product sales, co-manufacturing, and consignment. Under the co-manufacturing agreements, the Company is responsible for the manufacture of a finished good where the customer provides the majority of the raw materials. The Company controls the manufacturing process and the ultimate end-product before it is shipped to the customer. Based on these factors, the Company has determined that it is the principal in these agreements and therefore revenue is recognized in the gross amount of consideration the Company expects to be entitled for the goods provided. Royalty Revenues Royalty revenue consists of agreements with customers to use the Company’s intellectual property in exchange for a sales-based royalty. Royalties are considered over time revenue and are recorded in the HNH segment. Contract Liabilities The Company records contract liabilities when cash payments are received or due in advance of performance, including amounts which are refundable. The Company’s payment terms vary by the type and location of customers and the products offered. The term between invoicing and when payment is due is not significant. For certain products or services and customer types, the Company requires payment before the products are delivered to the customer. Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred because the amortization period would have been one year or less. These costs are recorded within selling and marketing expenses.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Information [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Cash paid during the nine months ended September 30, 2022 and 2021 for income taxes and interest is as follows: Nine Months Ended 2022 2021 Income taxes $ 26,277 $ 19,563 Interest $ 6,169 $ 3,492

ACCUMULATED OTHER COMPREHENSIVE

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	9 Months Ended
	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)	ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) The changes in accumulated other comprehensive (loss)/income were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net foreign currency translation adjustment $ (34,874) $ (3,362) $ (44,667) $ (7,981) Net change of cash flow hedge (see Note 20 for further information) Unrealized gain on cash flow hedge 564 450 3,770 1,583 Tax (137) (109) (920) (379) Net of tax 427 341 2,850 1,204 Net change in postretirement benefit plan (see Note 15 for further information) Amortization of prior service cost 2 18 6 55 Amortization of gain — (4) — (16) Gain arising during the period and prior service credit — — (41) (4) Total before tax 2 14 (35) 35 Tax — (3) (24) (9) Net of tax and adjustment 2 11 (59) 26 Total other comprehensive (loss)/income $ (34,445) $ (3,010) $ (41,876) $ (6,751) Included in "Net foreign currency translation adjustment" were gains of $5,065 and $10,151, related to a net investment hedge, which were net of taxes of $1,635 and $3,277 for the three and nine months ended September 30, 2022, respectively. Included in "Net foreign currency translation adjustment" were gains of $1,715 and $3,888, re lated to a net investment hedge, which were net of taxes of $553 and $1,243 for the three and nine months ended September 30, 2021, respectively. See Note 20, "Derivative Instruments and Hedging Activities." Accumulated other comprehensive (loss)/income at September 30, 2022 and December 31, 2021 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2021 $ (3,602) $ (1,631) $ 240 $ (4,993) Other comprehensive (loss)/income (44,667) 2,850 (59) (41,876) Balance September 30, 2022 $ (48,269) $ 1,219 $ 181 $ (46,869)

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	9 Months Ended
	Sep. 30, 2022
Retirement Benefits [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Defined Contribution Plans The Company sponsored two 401(k) savings plans for eligible employees, which were merged into one plan on January 1st, 2021. The remaining plan allows participants to make pretax contributions and the Company matches certain percentages of those pretax contributions. The remaining plan also has a discretionary profit sharing portion and matches 401(k) contributions with shares of the Company’s Common Stock. All amounts contributed to the plan are deposited into a trust fund administered by independent trustees. On June 21, 2022, the Company completed the acquisition of Kappa, which sponsors one defined contribution plan for its employees. In addition, on August 30, 2022, the Company completed the acquisition of Bergstrom, which sponsors one defined contribution plan for its employees. The plan allows participants to make pretax and after tax contributions. Bergstrom matches certain percentages of those contributions. Postretirement Medical Plans The Company provides postretirement benefits in the form of two unfunded postretirement medical plans; one that is under a collective bargaining agreement and covers eligible retired employees of the Verona facility and a plan for those named as executive officers in the Company’s proxy statement. Net periodic benefit costs for such retirement medical plans were as follows: Nine Months Ended 2022 2021 Service cost $ 59 $ 65 Interest cost 20 17 Amortization of prior service cost 6 55 Amortization of gain (1) (18) Net periodic benefit cost $ 84 $ 119 T he amounts recorded for these obligations on the Company’s condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021 are $1,247 and $1,293, respectively, and are included in "Other long-term obligations." These plans are unfunded and approved claims are paid from Company funds. Historical cash payments made under such plans have typically been less than $200 per year. Defined Benefit Pension Plans On May 27, 2019, the Company acquired Chemogas, which has an unfunded defined benefit pension plan. The plan provides for the payment of a lump sum at retirement or payments in case of death of the covered employees. The amounts recorded for these obligations on the Company's condensed consolidated balance sheets as of September 30, 2022 and December 31, 2021 were $607 and $684, respectively, and were included in "Other long-term obligations." Nine Months Ended 2022 2021 Service cost with interest to end of year $ 30 $ 52 Interest cost 12 11 Expected return on plan assets (26) (26) Amortization of gain — 2 Total net periodic benefit cost $ 16 $ 39 Deferred Compensation Plan

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at September 30, 2022 are as follows: Year October 1, 2022 to December 31, 2022 $ 1,111 2023 4,214 2024 4,053 2025 3,074 2026 2,678 2027 2,200 Thereafter 6,225 Total minimum lease payments $ 23,555 The Company’s Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983 because of dioxin contamination on portions of the site. Remediation was conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for certain potential liabilities associated with the Superfund site. In February 2022, BCP Ingredients, Inc. ("BCP"), the Company subsidiary that operates the site, along with the prior owner of the site received a Special Notice Letter from EPA for the performance of a focused remedial investigation/feasibility study ("RI/FS") at the site with regard to the presence of certain contaminants at the site, focusing primarily on the presence of 1,4 dioxane and chlorobenzene. BCP and the site's prior owner are currently negotiating with the EPA and the State of Missouri with respect to a proposed Administrative Settlement Agreement and Order on Consent that defines the scope and performance of the focused RI/FS. From time to time, the Company is involved in a variety of lawsuits, claims and proceedings, including those related to environmental matters. Subject to the uncertainties inherent in estimating future costs for contingent liabilities, except as expressly set forth in this note, management believes that any liability which may result from such matters will not have a material adverse effect on the Company’s consolidated financial position, results of operations, liquidity or cash flows.

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	FAIR VALUE OF FINANCIAL INSTRUMENTS The Company has a number of financial instruments, none of which are held for trading purposes. The Company estimates that the fair value of all financial instruments at September 30, 2022 and December 31, 2021 does not differ materially from the aggregate carrying values of its financial instruments recorded in the accompanying condensed consolidated balance sheets. The estimated fair value amounts have been determined by the Company using available market information and appropriate valuation methodologies. Considerable judgment is necessarily required in interpreting market data to develop the estimates of fair value, and, accordingly, the estimates are not necessarily indicative of the amounts that the Company could realize in a current market exchange. The carrying value of debt approximates fair value as the interest rate is based on market and the Company’s consolidated leverage ratio. The Company’s financial instruments also include cash equivalents, accounts receivable, accounts payable, and accrued liabilities, which are carried at cost and approximate fair value due to the short-term maturity of these instruments. Cash and cash equivalents at September 30, 2022 and December 31, 2021 includes $921 and $933 in money market funds, respectively. Non-current assets at September 30, 2022 and December 31, 2021 includes $8,032 and $6,267, respectively, of rabbi trust funds related to the Company's deferred compensation plan. The money market and rabbi trust funds are valued using level one inputs, as defined by ASC 820, “Fair Value Measurement.” The contingent consideration liabilities included on the balance sheet at of September 30, 2022 amount to $30,547 and were valued using level three inputs, as defined by ASC 820, "Fair Value Measurement".

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS The Company provides services under a contractual agreement to St. Gabriel CC Company, LLC. These services include accounting, information technology, quality control, and purchasing services, as well as operation of the St. Gabriel CC Company, LLC plant. The Company also sells raw materials to St. Gabriel CC Company, LLC. These raw materials are used in the production of finished goods that are, in turn, sold by Saint Gabriel CC Company, LLC to the Company for resale to unrelated parties.  As such, the sale of these raw materials to St. Gabriel CC Company, LLC in this scenario lacks economic substance and therefore the Company does not include them in net sales within the condensed consolidated statements of earnings. Payments for the services the Company provided amounted to $1,188 and $3,185 for the three and nine months ended September 30, 2022, respectively, and $901 and $2,648 for the three and nine months ended September 30, 2021, respectively. The raw materials purchased and subsequently sold amounted to $11,937 and $32,158 for the three and nine months ended September 30, 2022, respectively, and $6,419 and $18,461 for the three and nine months ended September 30, 2021, respectively. These services and raw materials are primarily recorded in cost of goods sold net of the finished goods received from St. Gabriel CC Company, LLC of $9,249 and $23,971 for the three and nine months ended September 30, 2022, respectively, and $4,944 and $14,545 for the three and nine months ended September 30, 2021, respectively. At September 30, 2022 and December 31, 2021, the Company had receivables of $13,126 and $10,504, respectively, recorded in accounts receivable from St. Gabriel CC Company, LLC for services rendered and raw materials sold. The Company also had payables of $9,339 and $7,552, respectively, recorded in accounts payable for finished goods received from St. Gabriel CC Company, LLC. In addition, the Company had receivables in the amount of $164 related to non-contractual monies owed from St. Gabriel CC Company, LLC, recorded in receivables as of December 31, 2021. There were no such receivables as of September 30, 2022. The Company had payables in the amount of $296 related to non-contractual monies owed to St. Gabriel CC Company, LLC, recorded in accounts payable as of both September 30, 2022 and December 31, 2021.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
LEASES	LEASESThe Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from September 30, 2022. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. On June 22, 2022, the Company signed a ten-year real estate sublease for approximately 40,000 square feet of office space, which will serve as the Company's corporate headquarters and a laboratory facility. The sublease will not commence until the sublandlord substantially completes its work per the sublease agreement, which will occur in the fourth quarter of 2022. The Company will recognize a right of use asset and a lease liability at the commencement date based on ASC 842, Lease Accounting. As of September 30, 2022 the Company did not record a right of use asset or lease liability on the balance sheet in connection with this lease. The Company has not identified any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the condensed consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2022: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At September 30, 2022 and December 31, 2021, the Company had finance lease liabilities of $2,345 and $2,470, respectively, which were recorded under "Lease liabilities" (current and non-current) on the condensed consolidated balance sheets. Right of use assets and lease liabilities at September 30, 2022 and December 31, 2021 are summarized as follows: Right of use assets September 30, 2022 December 31, 2021 Operating leases $ 11,617 $ 6,929 Finance leases 2,202 2,359 Total $ 13,819 $ 9,288 Lease liabilities - current September 30, 2022 December 31, 2021 Operating leases $ 3,727 $ 2,194 Finance leases 173 167 Total $ 3,900 $ 2,361 Lease liabilities - non-current September 30, 2022 December 31, 2021 Operating leases $ 8,069 $ 4,811 Finance leases 2,172 2,303 Total $ 10,241 $ 7,114 For the three and nine months ended September 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Cost Operating lease cost $ 1,190 $ 788 $ 2,782 $ 2,274 Finance lease cost Amortization of ROU asset 53 52 157 157 Interest on lease liabilities 30 32 91 98 Total finance lease 83 84 248 255 Total lease cost $ 1,273 $ 872 $ 3,030 $ 2,529 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,164 $ 761 $ 2,772 $ 2,249 Operating cash flows from finance leases 30 32 91 98 Financing cash flows from finance leases 42 40 125 118 $ 1,236 $ 833 $ 2,988 $ 2,465 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 2,275 $ 502 $ 7,552 $ 2,914 Weighted-average remaining lease term - operating leases 3.83 years 4.32 years 3.83 years 4.32 years Weighted-average remaining lease term - finance leases 10.65 years 11.67 years 10.65 years 11.67 years Weighted-average discount rate - operating leases 2.9 % 3.7 % 2.9 % 3.7 % Weighted-average discount rate - finance leases 5.1 % 5.1 % 5.1 % 5.1 %
LEASES	LEASESThe Company has both real estate leases and equipment leases. The main types of equipment leases include forklifts, trailers, printers and copiers, railcars, and trucks. Leases are categorized as both operating leases and finance leases. As a result of electing the practical expedient within ASU 2016-02, variable lease payments are combined and recognized on the balance sheet in the event that those charges and any related increases are explicitly stated in the lease. Such payments include common area maintenance charges, property taxes, and insurance charges and are recorded in the right of use asset and corresponding liability when the payments are stated in the lease with (a) fixed or in-substance fixed amounts, or (b) a variable payment based on an index or rate. Due to the acquisitive nature of the Company and the potential for synergies upon integration of acquired entities, the Company determined that the reasonably certain criterion could not be met for any renewal periods beginning two years from September 30, 2022. In addition, the Company has historically not been exercising purchase options under the equipment leases as it does not make economic sense to buy the equipment. Instead, the Company has historically replaced the equipment with new leases. Therefore, the Company determined that the reasonably certain criterion could not be met as it relates to purchase options. The Company has no residual value guarantees in lease transactions. On June 22, 2022, the Company signed a ten-year real estate sublease for approximately 40,000 square feet of office space, which will serve as the Company's corporate headquarters and a laboratory facility. The sublease will not commence until the sublandlord substantially completes its work per the sublease agreement, which will occur in the fourth quarter of 2022. The Company will recognize a right of use asset and a lease liability at the commencement date based on ASC 842, Lease Accounting. As of September 30, 2022 the Company did not record a right of use asset or lease liability on the balance sheet in connection with this lease. The Company has not identified any embedded leases. As indicated above, the Company elected the practical expedient to combine lease and non-lease components and recognizes the combined amount on the condensed consolidated balance sheet. Management determined that since the Company has a centralized treasury function, the parent company would either fund or guarantee a subsidiary's loan for borrowing over a similar term. As such, the Company's management determined it is appropriate to utilize a corporate based borrowing rate for all locations. The Company developed four tranches of leases based on lease terms and these tranches reflect the composition of the current lease portfolio. The Company's borrowing history shows that interest rates of a term loan or a line of credit depend on the duration of the loan rather than the nature of the assets purchased by those funds. Based on this understanding, the Company elected to use a portfolio approach to discount rates, applying corporate rates to the tranches of leases based on lease terms. Based on the Company's risk rating, the company applied the following discount rates for new leases entered into during 2022: (1) 1-2 years, 1.45% (2) 3-4 years, 2.04% (3) 5-9 years, 2.38% and (4) 10+ years, 3.10%. In connection with its December 2019 acquisition of Zumbro River Brand, Inc., the Company assumed the finance lease commitment for a warehouse, with an expiration date of March 31, 2033. The warehouse can be purchased at a pre-determined price beginning in 2023. At September 30, 2022 and December 31, 2021, the Company had finance lease liabilities of $2,345 and $2,470, respectively, which were recorded under "Lease liabilities" (current and non-current) on the condensed consolidated balance sheets. Right of use assets and lease liabilities at September 30, 2022 and December 31, 2021 are summarized as follows: Right of use assets September 30, 2022 December 31, 2021 Operating leases $ 11,617 $ 6,929 Finance leases 2,202 2,359 Total $ 13,819 $ 9,288 Lease liabilities - current September 30, 2022 December 31, 2021 Operating leases $ 3,727 $ 2,194 Finance leases 173 167 Total $ 3,900 $ 2,361 Lease liabilities - non-current September 30, 2022 December 31, 2021 Operating leases $ 8,069 $ 4,811 Finance leases 2,172 2,303 Total $ 10,241 $ 7,114 For the three and nine months ended September 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Cost Operating lease cost $ 1,190 $ 788 $ 2,782 $ 2,274 Finance lease cost Amortization of ROU asset 53 52 157 157 Interest on lease liabilities 30 32 91 98 Total finance lease 83 84 248 255 Total lease cost $ 1,273 $ 872 $ 3,030 $ 2,529 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,164 $ 761 $ 2,772 $ 2,249 Operating cash flows from finance leases 30 32 91 98 Financing cash flows from finance leases 42 40 125 118 $ 1,236 $ 833 $ 2,988 $ 2,465 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 2,275 $ 502 $ 7,552 $ 2,914 Weighted-average remaining lease term - operating leases 3.83 years 4.32 years 3.83 years 4.32 years Weighted-average remaining lease term - finance leases 10.65 years 11.67 years 10.65 years 11.67 years Weighted-average discount rate - operating leases 2.9 % 3.7 % 2.9 % 3.7 % Weighted-average discount rate - finance leases 5.1 % 5.1 % 5.1 % 5.1 %

DERIVATIVE INSTRUMENTS AND HEDG

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES	DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES The Company is exposed to market fluctuations in interest rates as well as variability in foreign exchange rates. In May 2019, the Company entered into an interest rate swap (cash flow hedge) with JP Morgan Chase, N.A. (the "Swap Counterparty") and a cross-currency swap (net investment hedge) with JP Morgan Chase, N.A. (the "Bank Counterparty"). The Company's primary objective for holding derivative financial instruments is to manage interest rate risk and foreign currency risk. On May 28, 2019, the Company entered into a pay-fixed (2.05%), receive-floating interest rate swap with a notional amount of $108,569 and a maturity date of June 27, 2023. The receive-floating interest rate was based on the London Interbank Offered Rate ("LIBOR") in the original trade agreement. Due to the discontinuation of LIBOR, in the third quarter of 2022, the Company modified its existing interest rate swap to reference 1-month CME Term SOFR (CME Group Benchmark Administration Limited as administrator of the forward-looking term Secured Overnight Financing Rate) in the amended trade terms. This modification was made under the relief provided for in ASC 848, "Reference Rate Reform" and therefore the derivative continues to qualify for hedge accounting. The Company's risk management objective and strategy with respect to the interest rate swap is to protect the Company against adverse fluctuations in interest rates by reducing its exposure to variability in cash flows relating to interest payments on a portion of its outstanding debt. The Company is meeting its objective since changes in the cash flows of the interest rate swap are expected to exactly offset the changes in the cash flows attributable to fluctuations in the contractually specified interest rate on the interest payments associated with the 2022 Credit Agreement. The net interest income related to the interest rate swap contract was $35 for the three months ended September 30, 2022. The net interest expense related to the interest rate swap contract was $842 for the nine months ended September 30, 2022, and $538 and $1,593 for the three and nine months ended September 30, 2021, respectively. The net interest income and expense were recorded in the condensed consolidated statements of earnings under "Interest expense, net." On May 28, 2019, the Company also entered into a pay-fixed (0.00%), receive-fixed (2.05%) cross-currency swap to manage foreign exchange risk related to the Company's net investment in Chemogas. The derivative has a notional amount of $108,569, an effective date of May 28, 2019, and a maturity date of June 27, 2023. The interest income related to the cross-currency swap contract was $569 and $1,682 for the three and nine months ended September 30, 2022, and $563 and $1,682 for the three and nine months ended September 30, 2021, respectively, which were recorded in the condensed consolidated statements of earnings under "Interest expense, net." The derivative instruments are with a single counterparty and are subject to a contractual agreement that provides for the net settlement of all contracts through a single payment in a single currency in the event of default on or termination of any one contract. As such, the derivative instruments are categorized as a master netting arrangement and presented as a net "Derivative asset" or "Derivative liability" on the condensed consolidated balance sheets. As of September 30, 2022 and December 31, 2021, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative assets (liabilities) September 30, 2022 December 31, 2021 Interest rate swap $ 1,612 $ (2,158) Cross-currency swap 12,928 (500) Derivative assets (liabilities) $ 14,540 $ (2,658) On a quarterly basis, the Company assesses whether the hedging relationship related to the interest rate swap is highly effective at achieving offsetting changes in cash flow attributable to the risk being hedged based on the following factors: (1) the key features and terms as enumerated above for the interest rate swap and hedged transactions match during the period (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. In addition, on a quarterly basis the Company assesses whether the hedging relationship related to the cross-currency swap is highly effective based on the following evaluations: (1) the Company will always have a sufficient amount of non-functional currency (EUR) net investment balance to at least meet the cross-currency notional amount until the maturity date of the hedge (2) it is probable that the Swap Counterparty will not default on its obligations under the swap, and (3) the Company performs a qualitative review each quarter to assess whether the relationship qualifies for hedge accounting. If any mismatches arise for either the interest rate swap or cross-currency swap, the Company will perform a regression analysis to determine if the hedged transaction is highly effective. If determined not to be highly effective, the Company will discontinue hedge accounting. As of September 30, 2022, the Company assessed the hedging relationships for the interest rate swap and cross-currency swap and determined them to be highly effective. As such, the net change in fair values of the derivative instruments was recorded in accumulated other comprehensive income. Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and nine months ended September 30, 2022 and 2021: Location within Statements of Comprehensive Income Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 427 $ 341 $ 2,850 $ 1,204 Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment 5,065 1,715 10,151 3,888 Total $ 5,492 $ 2,056 $ 13,001 $ 5,092 On June 21, 2022, the Company completed the acquisition of Kappa (as defined in Note 2 "Significant Acquisitions"). In the process of acquiring Kappa, the Company entered into four short-term foreign currency exchange forward contracts with JP Morgan Chase, N.A to manage fluctuations in foreign currency exchange rates related to the acquisition. The Company did not designate these contracts as hedged transactions under the applicable sections of ASC Topic 815, "Derivatives and Hedging". For the nine months ended September 30, 2022, the net gains on these forward contracts of $512 were recorded in other income or loss in the condensed consolidated statements of earnings. As of September 30, 2022, the Company did not maintain any open foreign currency exchange forward contracts as all four contracts expired before June 30, 2022. The following table summarizes the key terms of the four forward exchange contracts:. Date entered into Date expired on Balchem to sell Balchem to buy June 15, 2022 June 21, 2022 USD 294,555 NOK 2,924,553 June 15, 2022 June 17, 2022 USD 6,436 EUR 6,180 June 15, 2022 June 21, 2022 USD 16,640 EUR 15,972 June 15, 2022 June 21, 2022 EUR 15,972 NOK 165,210

CONDENSED CONSOLIDATED FINANC_2

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Policies)	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Certain reclassifications have been made to prior period amounts to conform with the current period's presentation.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Recently Adopted Accounting Standards In March 2020, the FASB issued Accounting Standards Update ("ASU") 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." This ASU provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued. The ASU is intended to help stakeholders during the global market-wide reference rate transition period. Therefore, this Standard Update is in effect from March 12, 2020 through December 31, 2022. In January 2021, the FASB issued ASU 2021-01, "Reference Rate Reform (Topic 848): Scope." ASU 2021-01 clarifies that certain optional expedients and exceptions in Topic 848 for contract modifications and hedge accounting apply to derivatives that are affected by the discounting transition. The ASU also amends the expedients and exceptions in Topic 848 to capture the incremental consequences of the scope clarification and to tailor the existing guidance to derivative instruments affected by the discounting transition. The Company adopted the Standard Update in 2021. Due to the discontinuation of LIBOR and under the relief provided by Topic 848, during the third quarter of 2022, the Company modified its existing interest rate swap and replaced LIBOR with 1-month CME Term SOFR (see Note 20, "Derivative Instruments and Hedging Activities "). The modification of the agreement did not have a significant impact on the Company's consolidated financial statements and disclosures. In December 2019, the FASB issued ASU 2019-12, "Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes." ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. ASU 2019-12 became effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company adopted ASU 2019-12 on January 1, 2021. The adoption of ASU 2019-12 did not have a significant impact on the Company's consolidated financial statements and disclosures.

SIGNIFICANT ACQUISITIONS (Table

SIGNIFICANT ACQUISITIONS (Tables)	9 Months Ended
	Sep. 30, 2022
Business Combination and Asset Acquisition [Abstract]
Schedule of Estimated Fair Value of Assets Acquired and Liabilities Assumed	The following table summarizes the estimated fair values of the assets acquired and liabilities assumed: Cash and cash equivalents $ 773 Accounts receivable 4,699 Inventories 3,922 Property, plant and equipment 2,700 Right of use assets 866 Customer relationships 26,500 Developed technology 4,700 Trademarks 2,300 Other assets 197 Accounts payable (685) Bank debt (206) Lease liabilities (871) Other liabilities (1,380) Goodwill 34,060 Total consideration on acquisition date 77,575 Contingent consideration liability (7,835) Amount paid to shareholders 69,740 To pay off bank debt and certain other obligations 1,152 Total amount paid $ 70,892 Cash and cash equivalents $ 6,365 Accounts receivable 8,036 Inventories 17,701 Property, plant and equipment 9,854 Right of use assets 3,349 Customer relationships 110,012 Developed technology 17,662 Trademarks 6,055 Other assets 2,399 Accounts payable (3,301) Bank debt (30,648) Lease liabilities (3,349) Other liabilities (4,373) Deferred income taxes, net (30,069) Goodwill 217,570 Total consideration on acquisition date 327,263 Contingent consideration liability (24,726) Net gain on foreign currency exchange forward contracts (512) Amount paid to shareholders 302,025 Kappa bank debt paid on acquisition date 30,648 Total amount paid on acquisition date $ 332,673

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	9 Months Ended
	Sep. 30, 2022
Stockholders' Equity Note [Abstract]
Schedule of Compensation Cost on Net Earnings	The Company’s results for the three and nine months ended September 30, 2022 and 2021 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings: Increase/(Decrease) for the Increase/(Decrease) for the Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Cost of sales $ 386 $ 444 $ 1,062 $ 1,188 Operating expenses 2,563 2,451 8,776 7,621 Net earnings (2,251) (2,232) (7,563) (6,801)
Schedule of Stock Option Activity	Option activity for the nine months ended September 30, 2022 and 2021 is summarized below: For the nine months ended September 30, 2022 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2021 867 $ 88.19 $ 69,711 Granted 239 139.04 Exercised (31) 70.06 Forfeited (12) 125.05 Canceled — — Outstanding as of September 30, 2022 1,063 $ 99.74 $ 27,308 6.6 Exercisable as of September 30, 2022 656 $ 81.45 $ 26,312 5.2 For the nine months ended September 30, 2021 Shares (000s) Weighted Aggregate Weighted Outstanding as of December 31, 2020 858 $ 80.58 $ 29,735 Granted 129 119.12 Exercised (100) 63.49 Forfeited (10) 106.93 Canceled (1) 74.57 Outstanding as of September 30, 2021 876 $ 87.91 $ 50,090 6.6 Exercisable as of September 30, 2021 540 $ 74.81 $ 37,961 5.5
Schedule of Other Information Pertaining to Stock Option Activity	Other information pertaining to option activity during the three and nine months ended September 30, 2022 and 2021 is as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Weighted-average fair value of options granted $ 48.55 $ — $ 44.77 $ 33.11 Total intrinsic value of stock options exercised ($000s) $ 815 $ 3,196 $ 1,964 $ 6,927
Schedule of Non-vested Restricted Stock Activity	Non-vested restricted stock activity for the nine months ended September 30, 2022 and 2021 is summarized below: Nine Months Ended September 30, 2022 2021 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 166 $ 99.70 159 $ 90.71 Granted 40 137.03 38 119.59 Vested (78) 81.11 (16) 86.79 Forfeited (7) 116.72 (5) 95.71 Non-vested balance as of September 30 121 $ 122.96 176 $ 97.17
Schedule of Non-vested Performance Share Activity	Non-vested performance share activity for the nine months ended September 30, 2022 and 2021 is summarized below: Nine Months Ended September 30, 2022 2021 Shares (000s) Weighted Shares (000s) Weighted Non-vested balance as of December 31 69 $ 110.72 71 $ 91.99 Granted 39 114.22 36 108.74 Vested (35) 53.17 (24) 70.64 Forfeited (3) 84.09 (11) 74.57 Non-vested balance as of September 30 70 $ 127.69 72 $ 110.22

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2022
Inventory Disclosure [Abstract]
Schedule of Inventories	Inventories at September 30, 2022 and December 31, 2021 consisted of the following: September 30, 2022 December 31, 2021 Raw materials $ 41,371 $ 28,639 Work in progress 11,879 10,563 Finished goods 86,214 51,856 Total inventories $ 139,464 $ 91,058

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property, plant and equipment at September 30, 2022 and December 31, 2021 are summarized as follows: September 30, 2022 December 31, 2021 Land $ 10,993 $ 11,692 Building 90,239 89,602 Equipment 267,611 253,995 Construction in progress 73,163 52,930 442,006 408,219 Less: accumulated depreciation 181,998 170,702 Property, plant and equipment, net $ 260,008 $ 237,517

INTANGIBLE ASSETS (Tables)

INTANGIBLE ASSETS (Tables)	9 Months Ended
	Sep. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Identifiable Intangible Assets	Identifiable intangible assets with finite lives at September 30, 2022 and December 31, 2021 are summarized as follows: Amortization Gross Carrying Amount at Accumulated Amortization at 9/30/2022 Gross Carrying Amount at 12/31/2021 Accumulated Amortization at 12/31/2021 Customer relationships & lists 10-20 $ 361,747 $ 185,381 $ 240,059 $ 173,489 Trademarks & trade names 2-17 50,487 32,285 43,116 28,985 Developed technology 5-12 40,816 15,524 20,234 14,607 Other 2-18 24,600 17,137 23,921 15,584 $ 477,650 $ 250,327 $ 327,330 $ 232,665

NET EARNINGS PER SHARE (Tables)

NET EARNINGS PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Reconciliation of the Net Earnings and Shares Used in Calculating Basic and Diluted Net Earnings Per Share	The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net Earnings - Basic and Diluted $ 25,249 $ 25,013 $ 83,961 $ 71,155 Shares (000s) Weighted Average Common Shares - Basic 32,010 32,194 32,017 32,227 Effect of Dilutive Securities – Stock Options, Restricted Stock, and Performance Shares 357 450 375 424 Weighted Average Common Shares - Diluted 32,367 32,644 32,392 32,651 Net Earnings Per Share - Basic $ 0.79 $ 0.78 $ 2.62 $ 2.21 Net Earnings Per Share - Diluted $ 0.78 $ 0.77 $ 2.59 $ 2.18

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The segment information is summarized as follows: Business Segment Assets September 30, December 31, Human Nutrition & Health $ 1,169,395 $ 727,131 Animal Nutrition & Health 189,652 158,971 Specialty Products 169,817 184,628 Other and Unallocated (1) 104,144 128,595 Total $ 1,633,008 $ 1,199,325 Business Segment Net Sales Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 142,655 $ 111,200 $ 396,728 $ 327,187 Animal Nutrition & Health 65,604 56,192 197,546 161,821 Specialty Products 29,641 27,615 99,622 89,645 Other and Unallocated (2) 6,367 2,862 15,931 7,237 Total $ 244,267 $ 197,869 $ 709,827 $ 585,890 Business Segment Earnings Before Income Taxes Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 20,584 $ 19,801 $ 64,592 $ 58,512 Animal Nutrition & Health 8,036 7,442 26,943 16,059 Specialty Products 7,105 6,455 24,785 23,373 Other and Unallocated (2) (2,100) (1,185) (4,439) (4,263) Interest and other expense (2,540) (428) (3,908) (1,594) Total $ 31,085 $ 32,085 $ 107,973 $ 92,087 Depreciation/Amortization Three Months Ended Nine Months Ended 2022 2021 2022 2021 Human Nutrition & Health $ 9,569 $ 7,472 $ 24,316 $ 22,486 Animal Nutrition & Health 1,681 1,932 5,010 5,512 Specialty Products 1,839 1,997 5,670 6,351 Other and Unallocated (2) 1,008 758 2,962 2,273 Total $ 14,097 $ 12,159 $ 37,958 $ 36,622 Capital Expenditures Nine Months Ended 2022 2021 Human Nutrition & Health $ 22,513 $ 14,492 Animal Nutrition & Health 8,748 4,557 Specialty Products 3,139 2,281 Other and Unallocated (2) 550 238 Total $ 34,950 $ 21,568 (1) Other and Unallocated assets consist of certain cash, capitalized loan issuance costs, other assets, investments, and income taxes, which the Company does not allocate to its individual business segments. It also includes assets associated with a few minor businesses which individually do not meet the quantitative thresholds for separate presentation. (2) Other and Unallocated consists of a few minor businesses which individually do not meet the quantitative thresholds for separate presentation and corporate expenses that have not been allocated to a segment. Unallocated corporate expenses consist of: (i) Transaction and integration costs, ERP implementation costs, and unallocated legal fees totaling $1,640 and $2,816 for the three and nine months ended September 30, 2022, respectively, and $305 and $1,005 for the three and nine months ended September 30, 2021, respectively, and (ii) Unallocated amortization expense of $855 and $2,475 for the three and nine months ended September 30, 2022, respectively, and $675 and $2,024 for the three and nine months ended September 30, 2021, respectively, related to an intangible asset in connection with a company-wide ERP system implementation and capitalized loan issuance costs that were included in interest expense in the Company's condensed consolidated statements of earnings.

REVENUE (Tables)

REVENUE (Tables)	9 Months Ended
	Sep. 30, 2022
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Revenues	The following table presents revenues disaggregated by revenue source. Sales and usage-based taxes are excluded from revenues. Three Months Ended Nine Months Ended 2022 2021 2022 2021 Product Sales $ 233,823 $ 188,573 $ 677,136 $ 557,683 Co-manufacturing 8,109 7,473 26,235 21,629 Consignment 1,484 829 4,064 3,260 Product Sales Revenue 243,416 196,875 707,435 582,572 Royalty Revenue 851 994 2,392 3,318 Total Revenue $ 244,267 $ 197,869 $ 709,827 $ 585,890 The following table presents revenues disaggregated by geography, based on the shipping addresses of customers: Three Months Ended Nine Months Ended 2022 2021 2022 2021 United States $ 174,564 $ 142,313 $ 518,131 $ 427,352 Foreign Countries 69,703 55,556 191,696 158,538 Total Revenue $ 244,267 $ 197,869 $ 709,827 $ 585,890

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2022
Supplemental Cash Flow Information [Abstract]
Schedule of Supplemental Cash Flow Information	Cash paid during the nine months ended September 30, 2022 and 2021 for income taxes and interest is as follows: Nine Months Ended 2022 2021 Income taxes $ 26,277 $ 19,563 Interest $ 6,169 $ 3,492

ACCUMULATED OTHER COMPREHENSI_2

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)	9 Months Ended
	Sep. 30, 2022
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Income (Loss)	The changes in accumulated other comprehensive (loss)/income were as follows: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Net foreign currency translation adjustment $ (34,874) $ (3,362) $ (44,667) $ (7,981) Net change of cash flow hedge (see Note 20 for further information) Unrealized gain on cash flow hedge 564 450 3,770 1,583 Tax (137) (109) (920) (379) Net of tax 427 341 2,850 1,204 Net change in postretirement benefit plan (see Note 15 for further information) Amortization of prior service cost 2 18 6 55 Amortization of gain — (4) — (16) Gain arising during the period and prior service credit — — (41) (4) Total before tax 2 14 (35) 35 Tax — (3) (24) (9) Net of tax and adjustment 2 11 (59) 26 Total other comprehensive (loss)/income $ (34,445) $ (3,010) $ (41,876) $ (6,751)
Schedule of Accumulated Other Comprehensive Income (Loss)	Accumulated other comprehensive (loss)/income at September 30, 2022 and December 31, 2021 consisted of the following: Foreign currency Cash flow hedge Postretirement Total Balance December 31, 2021 $ (3,602) $ (1,631) $ 240 $ (4,993) Other comprehensive (loss)/income (44,667) 2,850 (59) (41,876) Balance September 30, 2022 $ (48,269) $ 1,219 $ 181 $ (46,869)

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	9 Months Ended
	Sep. 30, 2022
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Cost	Net periodic benefit costs for such retirement medical plans were as follows: Nine Months Ended 2022 2021 Service cost $ 59 $ 65 Interest cost 20 17 Amortization of prior service cost 6 55 Amortization of gain (1) (18) Net periodic benefit cost $ 84 $ 119 Nine Months Ended 2022 2021 Service cost with interest to end of year $ 30 $ 52 Interest cost 12 11 Expected return on plan assets (26) (26) Amortization of gain — 2 Total net periodic benefit cost $ 16 $ 39

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Aggregate Future Minimum Rental Payments Required under Non-Cancelable Operating Leases	Aggregate future minimum rental payments required under all non-cancelable operating and finance leases at September 30, 2022 are as follows: Year October 1, 2022 to December 31, 2022 $ 1,111 2023 4,214 2024 4,053 2025 3,074 2026 2,678 2027 2,200 Thereafter 6,225 Total minimum lease payments $ 23,555

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Schedule of Right of Use Asset and Lease Liabilities	Right of use assets and lease liabilities at September 30, 2022 and December 31, 2021 are summarized as follows: Right of use assets September 30, 2022 December 31, 2021 Operating leases $ 11,617 $ 6,929 Finance leases 2,202 2,359 Total $ 13,819 $ 9,288 Lease liabilities - current September 30, 2022 December 31, 2021 Operating leases $ 3,727 $ 2,194 Finance leases 173 167 Total $ 3,900 $ 2,361 Lease liabilities - non-current September 30, 2022 December 31, 2021 Operating leases $ 8,069 $ 4,811 Finance leases 2,172 2,303 Total $ 10,241 $ 7,114
Schedule of Lease Cost	For the three and nine months ended September 30, 2022 and 2021, the Company's total lease costs were as follows, which included amounts recognized in earnings, amounts capitalized on the balance sheets, and the cash flows arising from lease transactions: Three Months Ended Nine Months Ended 2022 2021 2022 2021 Lease Cost Operating lease cost $ 1,190 $ 788 $ 2,782 $ 2,274 Finance lease cost Amortization of ROU asset 53 52 157 157 Interest on lease liabilities 30 32 91 98 Total finance lease 83 84 248 255 Total lease cost $ 1,273 $ 872 $ 3,030 $ 2,529 Cash paid for amounts included in the measurement of lease liabilities Operating cash flows from operating leases $ 1,164 $ 761 $ 2,772 $ 2,249 Operating cash flows from finance leases 30 32 91 98 Financing cash flows from finance leases 42 40 125 118 $ 1,236 $ 833 $ 2,988 $ 2,465 Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed $ 2,275 $ 502 $ 7,552 $ 2,914 Weighted-average remaining lease term - operating leases 3.83 years 4.32 years 3.83 years 4.32 years Weighted-average remaining lease term - finance leases 10.65 years 11.67 years 10.65 years 11.67 years Weighted-average discount rate - operating leases 2.9 % 3.7 % 2.9 % 3.7 % Weighted-average discount rate - finance leases 5.1 % 5.1 % 5.1 % 5.1 %

DERIVATIVE INSTRUMENTS AND HE_2

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES (Tables)	9 Months Ended
	Sep. 30, 2022
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Fair Value of Derivative Instruments	As of September 30, 2022 and December 31, 2021, the fair value of the derivative instruments is presented as follows in the Company's condensed consolidated balance sheets: Derivative assets (liabilities) September 30, 2022 December 31, 2021 Interest rate swap $ 1,612 $ (2,158) Cross-currency swap 12,928 (500) Derivative assets (liabilities) $ 14,540 $ (2,658)
Schedule of Gains (Losses) on Hedging Instruments	Losses and gains on our hedging instruments are recognized in accumulated other comprehensive income (loss) and categorized as follows for the three and nine months ended September 30, 2022 and 2021: Location within Statements of Comprehensive Income Three Months Ended September 30, Nine Months Ended 2022 2021 2022 2021 Cash flow hedge (interest rate swap), net of tax Unrealized gain/(loss) on cash flow hedge, net $ 427 $ 341 $ 2,850 $ 1,204 Net investment hedge (cross-currency swap), net of tax Net foreign currency translation adjustment 5,065 1,715 10,151 3,888 Total $ 5,492 $ 2,056 $ 13,001 $ 5,092
Summary Of Key Terms of Forward Exchange Contracts	The following table summarizes the key terms of the four forward exchange contracts:. Date entered into Date expired on Balchem to sell Balchem to buy June 15, 2022 June 21, 2022 USD 294,555 NOK 2,924,553 June 15, 2022 June 17, 2022 USD 6,436 EUR 6,180 June 15, 2022 June 21, 2022 USD 16,640 EUR 15,972 June 15, 2022 June 21, 2022 EUR 15,972 NOK 165,210

SIGNIFICANT ACQUISITIONS - Narr

SIGNIFICANT ACQUISITIONS - Narrative (Details) kr in Thousands				3 Months Ended		9 Months Ended
	Aug. 30, 2022 USD ($)	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 NOK (kr)	Dec. 31, 2021 USD ($)
Business Acquisition [Line Items]
Cash paid for acquisitions, net of cash acquired						$ 365,780,000	$ 0
Goodwill				$ 749,035,000		749,035,000			$ 523,949,000
Bergstrom
Business Acquisition [Line Items]
Payments	$ 70,892,000
Cash acquired from acquisition	773,000
Cash paid for acquisitions, net of cash acquired	68,967,000
Contingent consideration liability	7,835,000			7,835,000		7,835,000
Goodwill	34,060,000
Acquisition-related costs				593,000		668,000
Bergstrom | Former Shareholders
Business Acquisition [Line Items]
Payments	69,740,000
Bergstrom | Lenders
Business Acquisition [Line Items]
Payments	$ 1,152,000
Bergstrom | Customer relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired	15 years
Bergstrom | Corporate trademark
Business Acquisition [Line Items]
Useful life of intangible assets acquired	2 years
Bergstrom | Product trademarks
Business Acquisition [Line Items]
Useful life of intangible assets acquired	10 years
Bergstrom | Developed technology
Business Acquisition [Line Items]
Useful life of intangible assets acquired	12 years
Kappa
Business Acquisition [Line Items]
Payments		$ 332,673,000	kr 3,301,341
Cash acquired from acquisition		6,365,000	63,064
Cash paid for acquisitions, net of cash acquired		326,820,000	3,238,277
Contingent consideration liability		24,726,000		22,712,000		22,712,000		kr 245,000
Goodwill		217,570,000
Transaction and integration costs				$ 989,000		$ 1,440,000
Acquisition-related costs					$ 0		$ 0
Kappa | Former Shareholders
Business Acquisition [Line Items]
Payments		302,025,000	2,997,669
Cash paid for acquisitions, net of cash acquired		302,537,000
Kappa | Lenders
Business Acquisition [Line Items]
Payments		$ 30,648,000	kr 303,672
Kappa | Customer relationships
Business Acquisition [Line Items]
Useful life of intangible assets acquired		15 years	15 years
Kappa | Corporate trademark
Business Acquisition [Line Items]
Useful life of intangible assets acquired		2 years	2 years
Kappa | Product trademarks
Business Acquisition [Line Items]
Useful life of intangible assets acquired		10 years	10 years
Kappa | Developed technology
Business Acquisition [Line Items]
Useful life of intangible assets acquired		12 years	12 years

SIGNIFICANT ACQUISITIONS - Esti

SIGNIFICANT ACQUISITIONS - Estimated Fair Value of Assets Acquired and Liabilities Assumed (Details) kr in Thousands, $ in Thousands	Aug. 30, 2022 USD ($)	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 NOK (kr)	Dec. 31, 2021 USD ($)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Goodwill				$ 749,035		$ 523,949
Bergstrom
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents	$ 773
Accounts receivable	4,699
Inventories	3,922
Property, plant and equipment	2,700
Right of use assets	866
Other assets	197
Accounts payable	(685)
Bank debt	(206)
Lease liabilities	(871)
Other liabilities	(1,380)
Goodwill	34,060
Total consideration on acquisition date	77,575
Contingent consideration liability	(7,835)			(7,835)
Payments	70,892
Bergstrom | Former Shareholders
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Payments	69,740
Bergstrom | Lenders
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Payments	1,152
Bergstrom | Customer relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	26,500
Bergstrom | Developed technology
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	4,700
Bergstrom | Trademarks
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets	$ 2,300
Kappa
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Cash and cash equivalents		$ 6,365
Accounts receivable		8,036
Inventories		17,701
Property, plant and equipment		9,854
Right of use assets		3,349
Other assets		2,399
Accounts payable		(3,301)
Bank debt		(30,648)
Lease liabilities		(3,349)
Other liabilities		(4,373)
Deferred income taxes, net		(30,069)
Goodwill		217,570
Total consideration on acquisition date		327,263
Contingent consideration liability		(24,726)		$ (22,712)	kr (245,000)
Net gain on foreign currency exchange forward contracts		(512)
Payments		332,673	kr 3,301,341
Kappa | Former Shareholders
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Payments		302,025	2,997,669
Kappa | Lenders
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Payments		30,648	kr 303,672
Kappa | Customer relationships
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets		110,012
Kappa | Developed technology
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets		17,662
Kappa | Trademarks
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]
Intangible assets		$ 6,055

STOCKHOLDERS' EQUITY - Stock-Ba

STOCKHOLDERS' EQUITY - Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Net earnings	$ (2,251)	$ (2,232)	$ (7,563)	$ (6,801)
Expiration period of options granted			10 years
Shares available for future awards (in shares)	407,630		407,630
Stock options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			5 years
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Restricted stock | Non-employee director
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Vesting period			3 years
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 386	444	$ 1,062	1,188
Operating expenses
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock-based compensation cost	$ 2,563	$ 2,451	$ 8,776	$ 7,621

STOCKHOLDERS' EQUITY - Stock Op

STOCKHOLDERS' EQUITY - Stock Options (Details) - Stock options - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)			867	858
Granted (in shares)			239	129
Exercised (in shares)			(31)	(100)
Forfeited (in shares)			(12)	(10)
Canceled (in shares)			0	(1)
Outstanding at end of period (in shares)	1,063	876	1,063	876
Exercisable at end of period (in shares)	656	540	656	540
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding at beginning of period (in dollars per share)			$ 88.19	$ 80.58
Granted (in dollars per share)			139.04	119.12
Exercised (in dollars per share)			70.06	63.49
Forfeited (in dollars per share)			125.05	106.93
Canceled (in dollars per share)			0	74.57
Outstanding at end of period (in dollars per share)	$ 99.74	$ 87.91	99.74	87.91
Exercisable at end of period (in dollars per share)	$ 81.45	$ 74.81	$ 81.45	$ 74.81
Aggregate intrinsic value, outstanding, beginning of period			$ 69,711	$ 29,735
Aggregate intrinsic value, outstanding, end of period	$ 27,308	$ 50,090	27,308	50,090
Aggregate intrinsic value, exercisable, end of period	$ 26,312	$ 37,961	$ 26,312	$ 37,961
Weighted average remaining contractual term, outstanding			6 years 7 months 6 days	6 years 7 months 6 days
Weighted average remaining contractual term, exercisable			5 years 2 months 12 days	5 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Dividend yield rate			0.50%	0.50%
Expected volatility rate			30%	33%
Risk-free interest rate			2.80%	0.50%
Expected term			7 years 3 months 18 days	4 years 10 months 24 days
Weighted-average fair value of options granted (in dollars per share)	$ 48.55	$ 0	$ 44.77	$ 33.11
Total intrinsic value of stock options exercised	$ 815	$ 3,196	$ 1,964	$ 6,927

STOCKHOLDERS' EQUITY - Restrict

STOCKHOLDERS' EQUITY - Restricted Stock and Performance Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Unrecognized compensation cost	$ 23,665	$ 16,498
Period for unrecognized compensation cost to be recognized over	2 years 1 month 6 days
Estimated share-based compensation expense	$ 13,500
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	166	159
Granted (in shares)	40	38
Vested (in shares)	(78)	(16)
Forfeited (in shares)	(7)	(5)
Non-vested balance as of end of period (in shares)	121	176
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 99.70	$ 90.71
Granted (in dollars per share)	137.03	119.59
Vested (in dollars per share)	81.11	86.79
Forfeited (in dollars per share)	116.72	95.71
Non-vested balance as of end of period (in dollars per share)	$ 122.96	$ 97.17
Performance shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Non-vested balance as of beginning of period (in shares)	69	71
Granted (in shares)	39	36
Vested (in shares)	(35)	(24)
Forfeited (in shares)	(3)	(11)
Non-vested balance as of end of period (in shares)	70	72
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Non-vested balance as of beginning of period (in dollars per share)	$ 110.72	$ 91.99
Granted (in dollars per share)	114.22	108.74
Vested (in dollars per share)	53.17	70.64
Forfeited (in dollars per share)	84.09	74.57
Non-vested balance as of end of period (in dollars per share)	$ 127.69	$ 110.22
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Risk-free interest rate	1.80%	0.20%
Dividend yield rate	0.50%	0.60%
Expected volatility rate	32%	33%
Initial TSR	(15.70%)	11.70%
Cliff vest	100%

STOCKHOLDERS' EQUITY - Repurcha

STOCKHOLDERS' EQUITY - Repurchase of Common Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended			9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2020
Stockholders' Equity Note [Abstract]
Number of shares authorized to be repurchased (in shares)				3,763,038
Aggregate number of shares repurchased since inception (in shares)				3,069,266
Reclassification [Line Items]
Number of shares acquired under stock repurchase plan and subsequently reissued (in shares)				251,022	147,199
Treasury stock acquired, average cost (in dollars per share)				$ 140.41	$ 127.46
Revision of Prior Period, Reclassification, Adjustment
Reclassification [Line Items]
Repurchases of common stock	$ 11,080	$ 8,472	$ 2,210			$ 7,873

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 41,371	$ 28,639
Work in progress	11,879	10,563
Finished goods	86,214	51,856
Total inventories	$ 139,464	$ 91,058

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 442,006	$ 408,219
Less: accumulated depreciation	181,998	170,702
Property, plant and equipment, net	260,008	237,517
Land
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	10,993	11,692
Building
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	90,239	89,602
Equipment
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	267,611	253,995
Construction in progress
Property, Plant and Equipment [Abstract]
Gross property, plant and equipment	$ 73,163	$ 52,930

INTANGIBLE ASSETS - Narrative (

INTANGIBLE ASSETS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	$ 749,035,000		$ 749,035,000		$ 523,949,000
Amortization of identifiable intangible assets	7,922,000	$ 6,155,000	19,683,000	$ 18,868,000
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Remainder of 2021	5,300,000		5,300,000
2022	30,188,000		30,188,000
2023	21,740,000		21,740,000
2024	17,906,000		17,906,000
2025	17,362,000		17,362,000
2026	16,553,000		16,553,000
Identifiable intangible assets with indefinite useful lives	$ 0		$ 0		$ 0

INTANGIBLE ASSETS - Schedule of

INTANGIBLE ASSETS - Schedule of Identifiable Intangible Assets (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 477,650	$ 327,330
Accumulated amortization	250,327	232,665
Customer relationships & lists
Identifiable intangible assets [Abstract]
Gross carrying amount	361,747	240,059
Accumulated amortization	$ 185,381	173,489
Customer relationships & lists | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	10 years
Customer relationships & lists | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	20 years
Trademarks & trade names
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 50,487	43,116
Accumulated amortization	$ 32,285	28,985
Trademarks & trade names | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	2 years
Trademarks & trade names | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	17 years
Developed technology
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 40,816	20,234
Accumulated amortization	$ 15,524	14,607
Developed technology | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	5 years
Developed technology | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	12 years
Other
Identifiable intangible assets [Abstract]
Gross carrying amount	$ 24,600	23,921
Accumulated amortization	$ 17,137	$ 15,584
Other | Minimum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	2 years
Other | Maximum
Identifiable intangible assets [Abstract]
Amortization Period (in years)	18 years

EQUITY-METHOD INVESTMENT (Detai

EQUITY-METHOD INVESTMENT (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) vote	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Equity Method Investment, Summarized Financial Information [Abstract]
Percentage of operating expenses to be absorbed			66.66%
Percentage of production offtake			66.66%
St. Gabriel CC Company, LLC
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	66.66%		66.66%
Number of votes | vote			2
Loss relating to joint venture's expenses	$ 140	$ 142	$ 420	$ 416
Capital contributions	89	$ 46	222	$ 31
Carrying value of joint venture	$ 4,301		$ 4,301		$ 4,499
St. Gabriel CC Company, LLC | Eastman Chemical Company
Equity Method Investment, Summarized Financial Information [Abstract]
Ownership percentage in joint venture	33.34%		33.34%
Number of votes | vote			2

REVOLVING LOAN (Details)

REVOLVING LOAN (Details) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jul. 27, 2022	Dec. 31, 2021	Jun. 27, 2018
Debt Instrument [Line Items]
Proceeds from revolving loan				$ 435,000,000	$ 5,000,000
Repayments of outstanding balance				81,000,000	60,000,000
Capitalized costs net of accumulated amortization	$ 1,389,000			1,389,000			$ 421,000
Amortization expense pertaining to capitalized costs	$ 121,000		$ 71,000	$ 262,000	$ 212,000
Credit agreement
Debt Instrument [Line Items]
Interest rate	4.214%			4.214%
Commitment fee percentage				0.175%
Unused portion of revolving loan	$ 87,431,000			$ 87,431,000
Credit agreement | Minimum
Debt Instrument [Line Items]
Commitment fee percentage				0.15%
Credit agreement | Maximum
Debt Instrument [Line Items]
Commitment fee percentage				0.225%
Revolving loan | Revolving
Debt Instrument [Line Items]
Maximum borrowing capacity						$ 550,000,000		$ 500,000,000
Proceeds from revolving loan	70,000,000	$ 345,000,000
Repayments of outstanding balance				$ 433,569,000
Outstanding balance	$ 462,569,000			462,569,000			$ 108,569,000
Installment payments required				$ 0

NET EARNINGS PER SHARE (Details

NET EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Earnings Per Share [Abstract]
Net Earnings - Basic and Diluted	$ 25,249	$ 29,782	$ 28,930	$ 25,013	$ 22,731	$ 23,411	$ 83,961	$ 71,155
Weighted average common shares - basic (in shares)	32,010,000			32,194,000			32,017,000	32,227,000
Effect of dilutive securities - stock options, restricted stock, and performance shares (in shares)	357,000			450,000			375,000	424,000
Weighted average common shares - diluted (in shares)	32,367,000			32,644,000			32,392,000	32,651,000
Net earnings per share - basic (in dollars per share)	$ 0.79			$ 0.78			$ 2.62	$ 2.21
Net earnings per share - diluted (in dollars per share)	$ 0.78			$ 0.77			$ 2.59	$ 2.18
Anti-dilutive shares (in shares)	362,203			151,924			369,183	156,238

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Effective tax rate	18.80%	22%	22.20%	22.70%
Unrecognized tax benefits	$ 5,690		$ 5,690		$ 5,881
Accrued interest and penalties related to unrecognized tax benefits	$ 2,167		$ 2,167		$ 2,106

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	9 Months Ended
	Sep. 30, 2022 segment
Segment Reporting [Abstract]
Number of business segments	3

SEGMENT INFORMATION - Business

SEGMENT INFORMATION - Business Segment Assets (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Segment information [Abstract]
Assets	$ 1,633,008	$ 1,199,325
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Assets	1,169,395	727,131
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Assets	189,652	158,971
Operating segments | Specialty Products
Segment information [Abstract]
Assets	169,817	184,628
Other and unallocated
Segment information [Abstract]
Assets	$ 104,144	$ 128,595

SEGMENT INFORMATION - Busines_2

SEGMENT INFORMATION - Business Segment Net Sales (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment information [Abstract]
Net sales	$ 244,267	$ 197,869	$ 709,827	$ 585,890
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Net sales	142,655	111,200	396,728	327,187
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Net sales	65,604	56,192	197,546	161,821
Operating segments | Specialty Products
Segment information [Abstract]
Net sales	29,641	27,615	99,622	89,645
Other and unallocated
Segment information [Abstract]
Net sales	$ 6,367	$ 2,862	$ 15,931	$ 7,237

SEGMENT INFORMATION - Busines_3

SEGMENT INFORMATION - Business Segment Earnings Before Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment information [Abstract]
Earnings before income taxes	$ 31,085	$ 32,085	$ 107,973	$ 92,087
Interest and other (expense)	(2,540)	(428)	(3,908)	(1,594)
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	20,584	19,801	64,592	58,512
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Earnings before income taxes	8,036	7,442	26,943	16,059
Operating segments | Specialty Products
Segment information [Abstract]
Earnings before income taxes	7,105	6,455	24,785	23,373
Other and unallocated
Segment information [Abstract]
Earnings before income taxes	(2,100)	(1,185)	(4,439)	(4,263)
Interest and other expense
Segment information [Abstract]
Interest and other (expense)	$ (2,540)	$ (428)	$ (3,908)	$ (1,594)

SEGMENT INFORMATION - Depreciat

SEGMENT INFORMATION - Depreciation and Amortization (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment information [Abstract]
Depreciation and amortization	$ 14,097	$ 12,159	$ 37,958	$ 36,622
Operating segments | Human Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	9,569	7,472	24,316	22,486
Operating segments | Animal Nutrition & Health
Segment information [Abstract]
Depreciation and amortization	1,681	1,932	5,010	5,512
Operating segments | Specialty Products
Segment information [Abstract]
Depreciation and amortization	1,839	1,997	5,670	6,351
Other and unallocated
Segment information [Abstract]
Depreciation and amortization	$ 1,008	$ 758	$ 2,962	$ 2,273

SEGMENT INFORMATION - Capital E

SEGMENT INFORMATION - Capital Expenditures (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Segment information [Abstract]
Capital expenditures			$ 34,950	$ 21,568
Amortization of identifiable intangible assets	$ 7,922	$ 6,155	19,683	18,868
Other and unallocated
Segment information [Abstract]
Capital expenditures			550	238
Transaction and integration related costs	1,640	305	2,816	1,005
Amortization of identifiable intangible assets	$ 855	$ 675	2,475	2,024
Human Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			22,513	14,492
Animal Nutrition & Health | Operating segments
Segment information [Abstract]
Capital expenditures			8,748	4,557
Specialty Products | Operating segments
Segment information [Abstract]
Capital expenditures			$ 3,139	$ 2,281

REVENUE - Schedule of Disaggreg

REVENUE - Schedule of Disaggregation of Revenues (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) revenue_substream	Sep. 30, 2021 USD ($)
Revenue [Abstract]
Net sales	$ 244,267	$ 197,869	$ 709,827	$ 585,890
United States
Revenue [Abstract]
Net sales	174,564	142,313	518,131	427,352
Foreign Countries
Revenue [Abstract]
Net sales	69,703	55,556	191,696	158,538
Product Sales
Revenue [Abstract]
Net sales	233,823	188,573	677,136	557,683
Co-manufacturing
Revenue [Abstract]
Net sales	8,109	7,473	26,235	21,629
Consignment
Revenue [Abstract]
Net sales	1,484	829	4,064	3,260
Product Sales Revenue
Revenue [Abstract]
Net sales	243,416	196,875	$ 707,435	582,572
Number of sub-streams of revenue | revenue_substream			3
Royalty Revenue
Revenue [Abstract]
Net sales	$ 851	$ 994	$ 2,392	$ 3,318

SUPPLEMENTAL CASH FLOW INFORM_3

SUPPLEMENTAL CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Supplemental Cash Flow Information [Abstract]
Income taxes	$ 26,277	$ 19,563
Interest	$ 6,169	$ 3,492

ACCUMULATED OTHER COMPREHENSI_3

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Changes in Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Changes in accumulated other comprehensive income (loss) [Abstract]
Net foreign currency translation adjustment	$ (34,874)			$ (3,362)			$ (44,667)	$ (7,981)
Unrealized gain on cash flow hedge	564			450			3,770	1,583
Tax	(137)			(109)			(920)	(379)
Net of tax	427			341			2,850	1,204
Net change in postretirement benefit plan (see Note 15 for further information)
Amortization of prior service cost	2			18			6	55
Amortization of gain	0			(4)			0	(16)
Gain arising during the period and prior service credit	0			0			(41)	(4)
Total before tax	2			14			(35)	35
Tax	0			(3)			(24)	(9)
Net of tax and adjustment	2			11			(59)	26
Other comprehensive income (loss)	(34,445)	$ (6,135)	$ (1,296)	(3,010)	$ 1,883	$ (5,624)	(41,876)	(6,751)
Cross-currency swap
Net change in postretirement benefit plan (see Note 15 for further information)
Tax expense (benefit) on net investment hedge	1,635			553			3,277	1,243
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	5,065			1,715			10,151	3,888
Tax expense (benefit) on net investment hedge	$ 1,635			$ 553			$ 3,277	$ 1,243

ACCUMULATED OTHER COMPREHENSI_4

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) - Components of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 901,370	$ 873,682	$ 877,015	$ 869,642	$ 849,492	$ 828,233	$ 877,015	$ 828,233
Other comprehensive (loss)/income	(34,445)	(6,135)	(1,296)	(3,010)	1,883	(5,624)	(41,876)	(6,751)
Ending balance	895,922	901,370	873,682	889,078	869,642	849,492	895,922	889,078
Foreign currency translation adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(3,602)				(3,602)
Other comprehensive (loss)/income							(44,667)
Ending balance	(48,269)						(48,269)
Cash flow hedge
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			(1,631)				(1,631)
Other comprehensive (loss)/income							2,850
Ending balance	1,219						1,219
Postretirement benefit plan
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance			240				240
Other comprehensive (loss)/income							(59)
Ending balance	181						181
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(12,424)	(6,289)	(4,993)	432	(1,451)	4,173	(4,993)	4,173
Other comprehensive (loss)/income	(34,445)	(6,135)	(1,296)	(3,010)	1,883	(5,624)
Ending balance	$ (46,869)	$ (12,424)	$ (6,289)	$ (2,578)	$ 432	$ (1,451)	$ (46,869)	$ (2,578)

EMPLOYEE BENEFIT PLANS (Details

EMPLOYEE BENEFIT PLANS (Details) $ in Thousands			9 Months Ended		12 Months Ended
	Jun. 21, 2022 plan	Jan. 01, 2021 plan	Sep. 30, 2022 USD ($) plan	Sep. 30, 2021 USD ($)	Dec. 31, 2020 plan	Dec. 31, 2021 USD ($)
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | plan		1			2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Deferred compensation liability			$ 8,027			$ 6,270
Noncurrent deferred compensation liability			8,011			6,251
Current deferred compensation liability			16			19
Related rabbi trust assets			$ 8,032			6,267
Postretirement Medical Plans
Defined Benefit Plan Disclosure [Line Items]
Number of defined benefit plans | plan			2
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			$ 59	$ 65
Interest cost			20	17
Amortization of prior service cost			6	55
Amortization of gain			(1)	(18)
Net periodic benefit cost			84	119
Benefit obligation			1,247			1,293
Historical cash payments for retirement medical plan claims per year (less than)			200
Defined Benefit Pension Plans | Chemogas Defined Pension Plan
Defined Benefit Plan, Net Periodic Benefit Cost (Credit) [Abstract]
Service cost			30	52
Interest cost			12	11
Expected return on plan assets			(26)	(26)
Amortization of gain			0	2
Net periodic benefit cost			16	$ 39
Benefit obligation			$ 607			$ 684
Kappa
Defined Benefit Plan Disclosure [Line Items]
Number of savings plan | plan	1

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
October 1, 2022 to December 31, 2022	$ 1,111
2023	4,214
2024	4,053
2025	3,074
2026	2,678
2027	2,200
Thereafter	6,225
Total minimum lease payments	$ 23,555

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2022 USD ($) financial_instrument	Dec. 31, 2021 USD ($)
Fair value of financial instruments [Abstract]
Number of financial instruments held for trading purposes | financial_instrument	0
Related rabbi trust assets	$ 8,032	$ 6,267
Contingent consideration liabilities	30,547	0
Derivative assets (liabilities)	14,540	(2,658)
Cross-currency swap
Fair value of financial instruments [Abstract]
Derivative assets (liabilities)	12,928	(500)
Interest rate swap
Fair value of financial instruments [Abstract]
Derivative assets (liabilities)	1,612	(2,158)
Fair Value, Inputs, Level 2
Fair value of financial instruments [Abstract]
Contingent consideration liabilities	30,547
Money market funds | Level 1
Fair value of financial instruments [Abstract]
Cash and cash equivalents	$ 921	$ 933

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - St. Gabriel CC Company, LLC - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Related party transactions [Abstract]
Finished goods received from related party recorded in cost of goods sold	$ 9,249,000	$ 4,944,000	$ 23,971,000	$ 14,545,000
Receivable from related party	13,126,000		13,126,000		$ 10,504,000
Payables to related parties	9,339,000		9,339,000		7,552,000
Related party receivable related to non-contractual monies	0		0		164,000
Related party payable related to non-contractual monies	296,000		296,000		$ 296,000
Services provided
Related party transactions [Abstract]
Revenue from related party	1,188,000	901,000	3,185,000	2,648,000
Raw materials sold
Related party transactions [Abstract]
Revenue from related party	$ 11,937,000	$ 6,419,000	$ 32,158,000	$ 18,461,000

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) tranche	Sep. 30, 2021 USD ($)	Jun. 22, 2022 ft²	Dec. 31, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Reasonably certain criterion renewal period	2 years		2 years
Number of tranches | tranche			4
Finance lease liability	$ 2,345		$ 2,345			$ 2,470
Rent expense charged to operations under lease agreements	$ 1,190	$ 788	$ 2,782	$ 2,274
Corporate Headquarters And Laboratory Facility
Lessee, Lease, Description [Line Items]
Term of contract for operating leases					10 years
Office space | ft²					40,000
Years 1 and 2
Lessee, Lease, Description [Line Items]
Discount rate	1.45%		1.45%
Years 1 and 2 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	1 year		1 year
Years 1 and 2 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	2 years		2 years
Years 3 and 4
Lessee, Lease, Description [Line Items]
Discount rate	2.04%		2.04%
Years 3 and 4 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	3 years		3 years
Years 3 and 4 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	4 years		4 years
Years 5 and 9
Lessee, Lease, Description [Line Items]
Discount rate	2.38%		2.38%
Years 5 and 9 | Minimum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	5 years		5 years
Years 5 and 9 | Maximum
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	9 years		9 years
Years more than 10
Lessee, Lease, Description [Line Items]
Term of contract for operating leases	10 years		10 years
Discount rate	3.10%		3.10%

LEASES - Right-of-Use Assets an

LEASES - Right-of-Use Assets and Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Right of use assets
Right of use assets - operating leases	$ 11,617	$ 6,929
Finance Leases - ROU	2,202	2,359
Total right-of-use assets	13,819	9,288
Operating leases liabilities - current	3,727	2,194
Finance lease liabilities - current	173	167
Total lease liabilities, current	3,900	2,361
Operating leases liabilities - non-current	8,069	4,811
Finance lease liabilities - non-current	2,172	2,303
Total lease liabilities, non-current	$ 10,241	$ 7,114

LEASES - Schedule of Lease Cost

LEASES - Schedule of Lease Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Lease Cost
Operating lease cost	$ 1,190	$ 788	$ 2,782	$ 2,274
Amortization of ROU asset	53	52	157	157
Interest on lease liabilities	30	32	91	98
Total finance lease	83	84	248	255
Total lease cost	1,273	872	3,030	2,529
Cash paid for amounts included in the measurement of lease liabilities
Operating cash flows from operating leases	1,164	761	2,772	2,249
Operating cash flows from finance leases	30	32	91	98
Financing cash flows from finance leases	42	40	125	118
Cash flows from operating and finance leases	1,236	833	2,988	2,465
Right-of-use assets obtained in exchange for new operating lease liabilities, net of right-of-use assets disposed	$ 2,275	$ 502	$ 7,552	$ 2,914
Weighted-average remaining lease term - operating leases	3 years 9 months 29 days	4 years 3 months 25 days	3 years 9 months 29 days	4 years 3 months 25 days
Weighted-average remaining lease term - finance leases	10 years 7 months 24 days	11 years 8 months 1 day	10 years 7 months 24 days	11 years 8 months 1 day
Weighted-average discount rate - operating leases	2.90%	3.70%	2.90%	3.70%
Weighted-average discount rate - finance leases	5.10%	5.10%	5.10%	5.10%

DERIVATIVE INSTRUMENTS AND HE_3

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Narrative (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) derivative	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) derivative	Sep. 30, 2021 USD ($)	Jun. 21, 2022 derivative	May 28, 2019 USD ($)
Interest rate swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ 35	$ (538)	$ (842)	$ (1,593)
Forward Contracts
Derivative [Line Items]
Contracts | derivative	4		4		4
Net gains on forward contracts			$ 512
Designated as hedging instrument | Interest rate swap
Derivative [Line Items]
Notional amount of derivatives						$ 108,569
Designated as hedging instrument | Interest rate swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate						2.05%
Designated as hedging instrument | Cross-currency swap
Derivative [Line Items]
Notional amount of derivatives						$ 108,569
Designated as hedging instrument | Cross-currency swap | Interest expense
Derivative [Line Items]
Net interest income (expense)	$ 569	$ 563	$ 1,682	$ 1,682
Designated as hedging instrument | Cross-currency swap | Pay-fixed interest rate
Derivative [Line Items]
Fixed interest rate						0%
Designated as hedging instrument | Cross-currency swap | Receive-fixed interest rate
Derivative [Line Items]
Fixed interest rate						2.05%

DERIVATIVE INSTRUMENTS AND HE_4

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Fair Value of Derivative Instruments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Derivative Liability [Abstract]
Derivative assets (liabilities)	$ 14,540	$ (2,658)
Interest rate swap
Derivative Liability [Abstract]
Derivative assets (liabilities)	1,612	(2,158)
Cross-currency swap
Derivative Liability [Abstract]
Derivative assets (liabilities)	$ 12,928	$ (500)

DERIVATIVE INSTRUMENTS AND HE_5

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES - Schedule of Gains (Losses) on Hedging Instruments (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Derivative Instruments, Gain (Loss) [Line Items]
Gains and losses from hedging instruments recognized in AOCI	$ 5,492	$ 2,056	$ 13,001	$ 5,092
Interest rate swap
Derivative Instruments, Gain (Loss) [Line Items]
Cash flow hedge (interest rate swap), net of tax	427	341	2,850	1,204
Cross-currency swap
Derivative Instruments, Gain (Loss) [Line Items]
Net investment hedge (cross-currency swap), net of tax	$ 5,065	$ 1,715	$ 10,151	$ 3,888

DERIVATIVE INSTRUMENTS AND HE_6

DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES -Summary Of Key Terms of Forward Exchange Contracts (Details) - Not Designated as Hedging Instrument € in Thousands, kr in Thousands, $ in Thousands	Jun. 21, 2022 USD ($)	Jun. 21, 2022 NOK (kr)	Jun. 21, 2022 EUR (€)	Jun. 17, 2022 USD ($)	Jun. 17, 2022 EUR (€)
USD NOK Exchange
Derivative Instruments, Gain (Loss) [Line Items]
Notional value	$ 294,555	kr 2,924,553
USD EURO Exchange
Derivative Instruments, Gain (Loss) [Line Items]
Notional value	$ 16,640		€ 15,972	$ 6,436	€ 6,180
EURO NOK Exchange
Derivative Instruments, Gain (Loss) [Line Items]
Notional value		kr 165,210	€ 15,972